Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
stimulates	O
distinct	O
NF-kappa	O
B/rel	O
DNA	O
binding	O
activities	O
in	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

The	O
relationship	O
between	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
the	O
induction	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
was	O
examined	O
in	O
a	O
myeloid	B-cell_line
cell	I-cell_line
model	I-cell_line
of	O
HIV-1	O
infection	O
derived	O
from	O
the	O
PLB-985	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Chronic	O
infection	O
of	O
PLB-985	B-cell_line
cells	I-cell_line
led	O
to	O
increased	O
monocyte-specific	O
surface	O
marker	O
expression	O
,	O
increased	O
c-fms	O
gene	O
transcription	O
,	O
and	O
morphological	O
alterations	O
consistent	O
with	O
differentiation	O
along	O
the	O
monocytic	O
pathway	O
.	O

PLB-IIIB	B-cell_line
cells	I-cell_line
displayed	O
a	O
constitutive	O
NF-kappa	O
B-like	O
binding	O
activity	O
that	O
was	O
distinct	O
from	O
that	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
treatment	O
of	O
the	O
parental	B-cell_line
PLB-985	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
unique	O
DNA	O
binding	O
activity	O
consisted	O
of	O
proteins	O
of	O
70	B-protein
,	I-protein
90	I-protein
,	I-protein
and	I-protein
100	I-protein
kDa	I-protein
with	O
a	O
high	O
degree	O
of	O
binding	O
specificity	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
site	I-protein
within	O
the	O
PRDII	B-protein
domain	I-protein
of	O
beta	B-protein
interferon	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
characterize	O
the	O
nature	O
of	O
these	O
proteins	O
and	O
demonstrate	O
that	O
binding	O
of	O
these	O
proteins	O
is	O
also	O
induced	O
following	O
Sendai	O
paramyxovirus	O
infection	O
.	O

The	O
70-kDa	B-protein
protein	I-protein
corresponds	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
an	O
acute	O
paramyxovirus	O
infection	O
or	O
a	O
chronic	O
HIV-1	O
infection	O
.	O

Virus	O
infection	O
does	O
not	O
appear	O
to	O
alter	O
the	O
amount	O
of	O
RelA	B-protein
(	O
p65	B-protein
)	O
or	O
NFKB1	B-protein
(	O
p50	B-protein
)	O
but	O
rather	O
affects	O
the	O
capacity	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
sequester	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
,	O
therefore	O
leading	O
to	O
constitutive	O
levels	O
of	O
RelA	O
DNA	O
binding	O
activity	O
and	O
to	O
increased	O
levels	O
of	O
NF-kappa	O
B-dependent	O
gene	O
activity	O
.	O

The	O
virally	O
induced	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
have	O
a	O
distinct	O
binding	O
specificity	O
for	O
the	O
PRDII	B-DNA
domain	I-DNA
and	O
an	O
AT-rich	B-DNA
sequence	I-DNA
but	O
do	O
not	O
cross-react	O
with	O
NF-kappa	O
B	O
subunit-specific	O
antisera	O
directed	O
against	O
NFKB1	B-protein
(	O
p105	B-protein
or	O
p50	B-protein
)	O
,	O
NFKB2	B-protein
(	O
p100	B-protein
or	O
p52	B-protein
)	O
,	O
RelA	B-protein
(	O
p65	B-protein
)	O
,	O
or	O
c-rel	B-protein
.	O

DNA	O
binding	O
of	O
the	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
was	O
not	O
inhibited	O
by	O
recombinant	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
and	O
was	O
resistant	O
to	O
tryptic	O
digestion	O
,	O
suggesting	O
that	O
these	O
proteins	O
may	O
not	O
be	O
NF-kappa	B-protein
B	I-protein
related	I-protein
.	O

Transient	O
cotransfection	O
experiments	O
demonstrated	O
that	O
RelA	O
and	O
NFKB1	O
expression	O
maximally	O
stimulated	O
HIV-1	B-DNA
LTR-	I-DNA
and	I-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
reporter	I-DNA
genes	I-DNA
;	O
differences	O
in	O
NF-kappa	O
B-like	O
binding	O
activity	O
were	O
also	O
reflected	O
in	O
higher	O
constitutive	O
levels	O
of	O
NF-kappa	O
B-regulated	O
gene	O
expression	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O

JoUurNAL	NULL
or	NULL
Sept.	NULL
1993	NULL
,	NULL
p.	NULL
5235-5246	NULL
0022-538	NULL
X	NULL
,	NULL
/93/095235-12	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1993	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

67	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Chronic	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Infection	NULL
Stimulates	NULL
Distinct	NULL
NF-	NULL
«	NULL
xB/re/	NULL
DNA	NULL
Binding	NULL
Activities	NULL
in	NULL
Myelomonoblastic	NULL
Cells	NULL
ANNE	NULL
ROULSTON	NULL
,	NULL
*	NULL
PIERRE	NULL
BEAUPARLANT	NULL
,	NULL
*2	NULL
NANCY	NULL
RICE	NULL
,	NULL
``	NULL
anp	NULL
JOHN	NULL
HISCOTT_**	NULL
Lady	NULL
Davis	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
Sir	NULL
Mortimer	NULL
B.	NULL
Davis-Jewish	NULL
General	NULL
Hospital	NULL
,	NULL
**	NULL
and	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
McGill	NULL
University	NULL
,	NULL
``	NULL
Montreal	NULL
,	NULL
Quebec	NULL
H3T	NULL
1E2	NULL
,	NULL
Canada	NULL
,	NULL
and	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Virology	NULL
and	NULL
Carcinogenesis	NULL
,	NULL
ABL	NULL
Basic	NULL
Research	NULL
Program	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
Received	NULL
8	NULL
February	NULL
1993/Accepted	NULL
4	NULL
June	NULL
1993	NULL
The	NULL
relationship	NULL
between	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
NF-sB	NULL
binding	NULL
activity	NULL
was	NULL
examined	NULL
in	NULL
a	NULL
myeloid	NULL
cell	NULL
model	NULL
of	NULL
HIV-1	NULL
infection	NULL
derived	NULL
from	NULL
the	NULL
PLB-985	NULL
cell	NULL
line	NULL
.	NULL

Chronic	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
led	NULL
to	NULL
increased	NULL
monocyte-specific	NULL
surface	NULL
marker	NULL
expression	NULL
,	NULL
increased	NULL
c-fms	NULL
gene	NULL
transcription	NULL
,	NULL
and	NULL
morphological	NULL
alterations	NULL
consistent	NULL
with	NULL
differentiation	NULL
along	NULL
the	NULL
monocytic	NULL
pathway	NULL
.	NULL

PLB-IIIB	NULL
cells	NULL
displayed	NULL
a	NULL
constitutive	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
that	NULL
was	NULL
distinct	NULL
from	NULL
that	NULL
induced	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
or	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
treatment	NULL
of	NULL
the	NULL
parental	NULL
PLB-985	NULL
cell	NULL
line	NULL
.	NULL

This	NULL
unique	NULL
DNA	NULL
binding	NULL
activity	NULL
consisted	NULL
of	NULL
proteins	NULL
of	NULL
70	NULL
,	NULL
90	NULL
,	NULL
and	NULL
100	NULL
kDa	NULL
with	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
binding	NULL
specificity	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
within	NULL
the	NULL
PRDII	NULL
domain	NULL
of	NULL
beta	NULL
interferon	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
characterize	NULL
the	NULL
nature	NULL
of	NULL
these	NULL
proteins	NULL
and	NULL
demonstrate	NULL
that	NULL
binding	NULL
of	NULL
these	NULL
proteins	NULL
is	NULL
also	NULL
induced	NULL
following	NULL
Sendai	NULL
paramyxovirus	NULL
infection	NULL
.	NULL

The	NULL
70-kDa	NULL
protein	NULL
corresponds	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
cB	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
subunit	NULL
,	NULL
which	NULL
is	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
an	NULL
acute	NULL
paramyxovirus	NULL
infection	NULL
or	NULL
a	NULL
chronic	NULL
HIV-1	NULL
infection	NULL
.	NULL

Virus	NULL
infection	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
alter	NULL
the	NULL
amount	NULL
of	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
or	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
but	NULL
rather	NULL
affects	NULL
the	NULL
capacity	NULL
of	NULL
IBa	NULL
to	NULL
sequester	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
therefore	NULL
leading	NULL
to	NULL
constitutive	NULL
levels	NULL
of	NULL
RelA	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
to	NULL
increased	NULL
levels	NULL
of	NULL
NF-B-dependent	NULL
gene	NULL
activity	NULL
.	NULL

The	NULL
virally	NULL
induced	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
have	NULL
a	NULL
distinct	NULL
binding	NULL
specificity	NULL
for	NULL
the	NULL
PRDII	NULL
domain	NULL
and	NULL
an	NULL
AT-rich	NULL
sequence	NULL
but	NULL
do	NULL
not	NULL
cross-react	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
subunit-specific	NULL
antisera	NULL
directed	NULL
against	NULL
NFKBI1	NULL
(	NULL
p105	NULL
or	NULL
p50	NULL
)	NULL
,	NULL
NFKB2	NULL
(	NULL
p100	NULL
or	NULL
pS2	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
or	NULL
c-re/	NULL
.	NULL

DNA	NULL
binding	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
recombinant	NULL
IBao/MAD-3	NULL
and	NULL
was	NULL
resistant	NULL
to	NULL
tryptic	NULL
digestion	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
proteins	NULL
may	NULL
not	NULL
be	NULL
NF-	NULL
«	NULL
B	NULL
related	NULL
.	NULL

Transient	NULL
cotransfection	NULL
experiments	NULL
demonstrated	NULL
that	NULL
RelA	NULL
and	NULL
NFKB1	NULL
expression	NULL
maximally	NULL
stimulated	NULL
HIV-1	NULL
LTR-	NULL
and	NULL
NF-B-dependent	NULL
reporter	NULL
genes	NULL
;	NULL
differences	NULL
in	NULL
NF-xB-like	NULL
binding	NULL
activity	NULL
were	NULL
also	NULL
reflected	NULL
in	NULL
higher	NULL
constitutive	NULL
levels	NULL
of	NULL
NF-xB-regulated	NULL
gene	NULL
expression	NULL
in	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
.	NULL

CD4*	NULL
cells	NULL
of	NULL
the	NULL
monocyte-macrophage	NULL
lineage	NULL
,	NULL
including	NULL
myeloid	NULL
progenitor	NULL
cells	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
(	NULL
14	NULL
,	NULL
53	NULL
)	NULL
;	NULL
these	NULL
cells	NULL
may	NULL
serve	NULL
as	NULL
intracellular	NULL
reservoirs	NULL
for	NULL
virus	NULL
and	NULL
contribute	NULL
to	NULL
the	NULL
spread	NULL
of	NULL
HIV-1	NULL
to	NULL
peripheral	NULL
tissues	NULL
,	NULL
such	NULL
as	NULL
the	NULL
skin	NULL
,	NULL
lungs	NULL
,	NULL
brain	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
(	NULL
39	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
physiological	NULL
consequences	NULL
associated	NULL
with	NULL
HIV-1	NULL
infection	NULL
of	NULL
monocytic	NULL
cells	NULL
is	NULL
altered	NULL
regulation	NULL
of	NULL
inflammatory	NULL
cytokine	NULL
production	NULL
(	NULL
12	NULL
,	NULL
13	NULL
,	NULL
54	NULL
)	NULL
;	NULL
alterations	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
cytokines	NULL
in	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
may	NULL
involve	NULL
either	NULL
increased	NULL
or	NULL
decreased	NULL
cytokine	NULL
levels	NULL
,	NULL
depending	NULL
on	NULL
a	NULL
number	NULL
of	NULL
interrelated	NULL
variables	NULL
:	NULL
the	NULL
inducing	NULL
agent	NULL
,	NULL
the	NULL
cell	NULL
types	NULL
used	NULL
in	NULL
the	NULL
study	NULL
,	NULL
and	NULL
the	NULL
state	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Conversely	NULL
,	NULL
cytokines	NULL
exert	NULL
differential	NULL
effects	NULL
on	NULL
HIV-1	NULL
gene	NULL
expression	NULL
;	NULL
interleukin-1	NULL
(	NULL
IL-1	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
IL-6	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha/beta	NULL
(	NULL
TNF-	NULL
«	NULL
/	NULL
B	NULL
)	NULL
,	NULL
and	NULL
granulocyte-monocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
,	NULL
whereas	NULL
alpha/beta	NULL
interferon	NULL
(	NULL
IFN-	NULL
«	NULL
a/B	NULL
)	NULL
decreases	NULL
HIV-1	NULL
activity	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Cytokines	NULL
have	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS-associated	NULL
malignancies	NULL
,	NULL
such	NULL
as	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
and	NULL
B-cell	NULL
lymphoma	NULL
(	NULL
20	NULL
)	NULL
,	NULL
and	NULL
may	NULL
contribute	NULL
to	NULL
fever	NULL
,	NULL
cachexia	NULL
,	NULL
and	NULL
other	NULL
clinical	NULL
symptoms	NULL
(	NULL
7	NULL
,	NULL
40	NULL
)	NULL
.	NULL

*	NULL
Corresponding	NULL
author	NULL
.	NULL

5235	NULL
One	NULL
pathway	NULL
by	NULL
which	NULL
cytokine	NULL
expression	NULL
and	NULL
viral	NULL
gene	NULL
expression	NULL
may	NULL
be	NULL
coordinately	NULL
regulated	NULL
is	NULL
through	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
9	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B/rel	NULL
participates	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
many	NULL
immunoregulatory	NULL
cytokine	NULL
genes	NULL
and	NULL
cell	NULL
surface	NULL
receptors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
several	NULL
viral	NULL
enhanc-ers	NULL
,	NULL
including	NULL
those	NULL
of	NULL
cytomegalovirus	NULL
,	NULL
simian	NULL
virus	NULL
40	NULL
,	NULL
and	NULL
HIV-1	NULL
,	NULL
contain	NULL
NF-	NULL
«	NULL
B	NULL
recognition	NULL
sites	NULL
.	NULL

The	NULL
consensus	NULL
recognition	NULL
site	NULL
is	NULL
a	NULL
decamer	NULL
with	NULL
two	NULL
pentameric	NULL
half	NULL
sites	NULL
,	NULL
each	NULL
of	NULL
which	NULL
participates	NULL
in	NULL
the	NULL
recognition	NULL
and	NULL
stabilization	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
dimer	NULL
(	NULL
70	NULL
)	NULL
.	NULL

While	NULL
constitutive	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
has	NULL
been	NULL
detected	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
and	NULL
monocytes	NULL
(	NULL
23	NULL
,	NULL
50	NULL
)	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
is	NULL
inducible	NULL
in	NULL
most	NULL
cell	NULL
types	NULL
by	NULL
viruses	NULL
,	NULL
double-stranded	NULL
RNA	NULL
,	NULL
bacterial	NULL
lipopolysaccharides	NULL
,	NULL
cyto-kines	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
and	NULL
oxygen	NULL
radical	NULL
intermediates	NULL
(	NULL
26	NULL
,	NULL
37	NULL
,	NULL
62	NULL
,	NULL
63	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
was	NULL
initially	NULL
described	NULL
as	NULL
two	NULL
subunits	NULL
,	NULL
p50	NULL
(	NULL
NFKB1	NULL
)	NULL
and	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
,	NULL
that	NULL
existed	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
a	NULL
latent	NULL
form	NULL
complexed	NULL
to	NULL
an	NULL
inhibitory	NULL
subunit	NULL
,	NULL
IB	NULL
.	NULL

Induction	NULL
resulted	NULL
in	NULL
the	NULL
release	NULL
of	NULL
IxB	NULL
from	NULL
p50-p65	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
heterodimer	NULL
(	NULL
3	NULL
,	NULL
18	NULL
)	NULL
.	NULL

It	NULL
is	NULL
now	NULL
apparent	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
constitute	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
whose	NULL
genes	NULL
share	NULL
homology	NULL
in	NULL
the	NULL
N-terminal	NULL
DNA	NULL
binding	NULL
domain	NULL
with	NULL
the	NULL
c-re/	NULL
proto-oncogene	NULL
and	NULL
with	NULL
the	NULL
Drosophila	NULL
morphogen	NULL
dorsal	NULL
(	NULL
4	NULL
,	NULL
8	NULL
,	NULL
9	NULL
,	NULL
21	NULL
)	NULL
.	NULL

5236	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

The	NULL
family	NULL
includes	NULL
several	NULL
members	NULL
:	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
is	NULL
synthesized	NULL
as	NULL
a	NULL
105-kDa	NULL
non-DNA	NULL
binding	NULL
precursor	NULL
that	NULL
is	NULL
proteolytically	NULL
cleaved	NULL
to	NULL
yield	NULL
the	NULL
mature	NULL
p50	NULL
product	NULL
(	NULL
10	NULL
,	NULL
19	NULL
,	NULL
32	NULL
,	NULL
41	NULL
)	NULL
.	NULL

The	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
protein	NULL
contains	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
N-terminal	NULL
rel	NULL
homology	NULL
domain	NULL
a	NULL
trans-activation	NULL
domain	NULL
in	NULL
its	NULL
C-terminal	NULL
portion	NULL
(	NULL
21	NULL
,	NULL
45	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
an	NULL
alternatively	NULL
spliced	NULL
form	NULL
of	NULL
RelA	NULL
,	NULL
termed	NULL
AReIA	NULL
(	NULL
p6SA	NULL
)	NULL
,	NULL
was	NULL
identified	NULL
;	NULL
it	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
and	NULL
has	NULL
a	NULL
distinct	NULL
trans-dominant	NULL
negative	NULL
effect	NULL
on	NULL
transcription	NULL
(	NULL
43	NULL
,	NULL
58	NULL
)	NULL
.	NULL

c-rel	NULL
(	NULL
p85	NULL
)	NULL
is	NULL
the	NULL
cellular	NULL
homolog	NULL
of	NULL
v-re/	NULL
,	NULL
the	NULL
transforming	NULL
gene	NULL
of	NULL
the	NULL
reticuloendotheliosis	NULL
virus	NULL
,	NULL
an	NULL
avian	NULL
retrovirus	NULL
that	NULL
induces	NULL
acute	NULL
fatal	NULL
lymphoma	NULL
in	NULL
young	NULL
birds	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
NFKB2	NULL
(	NULL
p100	NULL
,	NULL
p52	NULL
,	NULL
and	NULL
lyt-10	NULL
)	NULL
gene	NULL
encodes	NULL
a	NULL
100-kDa	NULL
precursor	NULL
(	NULL
p100	NULL
)	NULL
and	NULL
a	NULL
52-kDa	NULL
product	NULL
and	NULL
corresponds	NULL
to	NULL
lyt-10	NULL
,	NULL
originally	NULL
identified	NULL
in	NULL
a	NULL
chromosomal	NULL
translocation	NULL
associated	NULL
with	NULL
B-cell	NULL
lymphoma	NULL
(	NULL
44	NULL
,	NULL
60	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
68-kDa	NULL
protein	NULL
referred	NULL
to	NULL
as	NULL
relB	NULL
(	NULL
I-rel	NULL
)	NULL
was	NULL
cloned	NULL
;	NULL
relB	NULL
appears	NULL
to	NULL
form	NULL
activating	NULL
heterodimers	NULL
with	NULL
the	NULL
p50	NULL
protein	NULL
(	NULL
57	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Multiple	NULL
ankyrin	NULL
repeat-containing	NULL
IxB	NULL
proteins	NULL
that	NULL
regulate	NULL
cytoplasmic	NULL
anchoring	NULL
and	NULL
nuclear	NULL
uptake	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
have	NULL
also	NULL
been	NULL
defined	NULL
(	NULL
4	NULL
,	NULL
8	NULL
,	NULL
9	NULL
)	NULL
:	NULL
IxBa	NULL
(	NULL
MAD-3/pp40/	NULL
RL/IF-1	NULL
)	NULL
,	NULL
cloned	NULL
as	NULL
an	NULL
immediate-early	NULL
gene	NULL
in	NULL
monocytes	NULL
(	NULL
25	NULL
)	NULL
,	NULL
interacts	NULL
with	NULL
high	NULL
affinity	NULL
with	NULL
RelA	NULL
and	NULL
inhibits	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
-RelA	NULL
(	NULL
p65	NULL
)	NULL
or	NULL
NFKB2	NULL
(	NULL
p52	NULL
)	NULL
-RelA	NULL
heterodimers	NULL
and	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
homodimers	NULL
;	NULL
IxBa	NULL
is	NULL
also	NULL
capable	NULL
of	NULL
interacting	NULL
with	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
c-re/	NULL
with	NULL
low	NULL
affinity	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
association	NULL
of	NULL
IxBa	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
occurs	NULL
via	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
,	NULL
and	NULL
in	NULL
the	NULL
uninduced	NULL
state	NULL
,	NULL
IxB	NULL
masks	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
(	NULL
NLS	NULL
)	NULL
to	NULL
prevent	NULL
nuclear	NULL
translocation	NULL
(	NULL
6	NULL
,	NULL
29	NULL
,	NULL
31	NULL
,	NULL
72	NULL
)	NULL
.	NULL

Bcel3	NULL
(	NULL
and	NULL
ABcI3	NULL
)	NULL
is	NULL
the	NULL
product	NULL
of	NULL
a	NULL
gene	NULL
associated	NULL
with	NULL
the	NULL
t	NULL
(	NULL
14	NULL
;	NULL
19	NULL
)	NULL
chromosomal	NULL
translocation	NULL
in	NULL
chronic	NULL
lymphocytic	NULL
leuke-mia	NULL
.	NULL

Bcl3	NULL
specifically	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
or	NULL
NFKB2	NULL
(	NULL
p52	NULL
)	NULL
homodimers	NULL
(	NULL
15	NULL
,	NULL
30	NULL
,	NULL
71	NULL
)	NULL
.	NULL

IxBy	NULL
is	NULL
a	NULL
murine	NULL
70-kDa	NULL
protein	NULL
derived	NULL
from	NULL
the	NULL
carboxy-terminal	NULL
607	NULL
amino	NULL
acids	NULL
of	NULL
p105	NULL
by	NULL
alternative	NULL
splicing	NULL
.	NULL

This	NULL
protein	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
-RelA	NULL
heterodimers	NULL
,	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
homodimers	NULL
,	NULL
and	NULL
c-re/	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
p105	NULL
precursor	NULL
itself	NULL
was	NULL
shown	NULL
to	NULL
inhibit	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-rel	NULL
and	NULL
RelA	NULL
;	NULL
additionally	NULL
,	NULL
p105	NULL
generates	NULL
nuclear	NULL
RelA-p50	NULL
and	NULL
p50-c-rel	NULL
complexes	NULL
through	NULL
proteolytic	NULL
processing	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
now	NULL
examined	NULL
the	NULL
relationship	NULL
among	NULL
HIV-1	NULL
infection	NULL
of	NULL
myeloid	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
(	NULL
2	NULL
,	NULL
23	NULL
,	NULL
47	NULL
,	NULL
50	NULL
,	NULL
64	NULL
)	NULL
,	NULL
cellular	NULL
differentiation	NULL
(	NULL
1	NULL
,	NULL
17	NULL
,	NULL
46	NULL
)	NULL
,	NULL
and	NULL
HIV-1	NULL
gene	NULL
expression	NULL
(	NULL
38	NULL
,	NULL
67	NULL
)	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
established	NULL
a	NULL
population	NULL
of	NULL
HIV-1-infected	NULL
myelomonoblastic	NULL
cells	NULL
(	NULL
PLB-IIIB	NULL
)	NULL
derived	NULL
from	NULL
the	NULL
PLB-985	NULL
cell	NULL
line	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Chronic	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
led	NULL
to	NULL
increased	NULL
monocyte-specific	NULL
surface	NULL
marker	NULL
expression	NULL
,	NULL
increased	NULL
c-fms	NULL
gene	NULL
transcription	NULL
,	NULL
and	NULL
morphological	NULL
alterations	NULL
consistent	NULL
with	NULL
differentiation	NULL
along	NULL
the	NULL
monocytic	NULL
pathway	NULL
(	NULL
55	NULL
)	NULL
.	NULL

PLB-IIIB	NULL
cells	NULL
displayed	NULL
a	NULL
constitutive	NULL
NFKB-like	NULL
binding	NULL
activity	NULL
consisting	NULL
of	NULL
proteins	NULL
of	NULL
70	NULL
,	NULL
90	NULL
,	NULL
and	NULL
100	NULL
kDa	NULL
with	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
binding	NULL
specificity	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
within	NULL
the	NULL
PRDII	NULL
domain	NULL
of	NULL
IFN-B	NULL
(	NULL
P2	NULL
)	NULL
(	NULL
55	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
characterize	NULL
the	NULL
nature	NULL
of	NULL
these	NULL
proteins	NULL
and	NULL
demonstrate	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
these	NULL
proteins	NULL
is	NULL
also	NULL
induced	NULL
following	NULL
Sendai	NULL
paramyxovirus	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
.	NULL

The	NULL
70-kDa	NULL
protein	NULL
corresponds	NULL
to	NULL
'the	NULL
NF-	NULL
«	NULL
B	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
subunit	NULL
,	NULL
which	NULL
is	NULL
specifically	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
a	NULL
viral	NULL
infection	NULL
.	NULL

The	NULL
virally	NULL
induced	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
have	NULL
a	NULL
distinct	NULL
binding	NULL
specificity	NULL
for	NULL
the	NULL
PRDII	NULL
domain	NULL
and	NULL
an	NULL
AT-rich	NULL
sequence	NULL
but	NULL
do	NULL
not	NULL
cross-react	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
subunit-specific	NULL
antisera	NULL
directed	NULL
against	NULL
J.	NULL
Viror	NULL
.	NULL

RelA	NULL
,	NULL
NFKB1	NULL
(	NULL
p105	NULL
or	NULL
p50	NULL
)	NULL
,	NULL
NFKB2	NULL
(	NULL
p100	NULL
or	NULL
p52	NULL
)	NULL
,	NULL
or	NULL
c-re/	NULL
.	NULL

Transient	NULL
transfection	NULL
experiments	NULL
demonstrated	NULL
that	NULL
differences	NULL
in	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
were	NULL
reflected	NULL
in	NULL
higher	NULL
constitutive	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B-regulated	NULL
gene	NULL
expression	NULL
in	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
and	NULL
transfections	NULL
.	NULL

PLB-985	NULL
cells	NULL
(	NULL
66	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
strain	NULL
IIIB	NULL
as	NULL
previously	NULL
described	NULL
by	NULL
use	NULL
of	NULL
supernatants	NULL
from	NULL
HIV-l-infected	NULL
U937	NULL
cells	NULL
to	NULL
establish	NULL
the	NULL
chronically	NULL
infected	NULL
PLB-IIIB	NULL
cell	NULL
line	NULL
(	NULL
55	NULL
)	NULL
.	NULL

PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
,	NULL
Life	NULL
Technologies	NULL
Inc.	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Hyclone	NULL
,	NULL
Logan	NULL
,	NULL
Utah	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
20	NULL
pg	NULL
of	NULL
gentamicin	NULL
(	NULL
Schering	NULL
Canada	NULL
,	NULL
Pointe	NULL
Claire	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Exponentially	NULL
growing	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
follows	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
individual	NULL
experimental	NULL
protocol	NULL
:	NULL
addition	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
25	NULL
ng/ml	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

;	NULL
addition	NULL
of	NULL
TNF-a	NULL
at	NULL
100	NULL
U/ml	NULL
(	NULL
Genzyme	NULL
Inc.	NULL
,	NULL
Kneeland	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

;	NULL
and	NULL
priming	NULL
with	NULL
IFN-	NULL
«	NULL
2	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Schering	NULL
Canada	NULL
)	NULL
for	NULL
4	NULL
h	NULL
at	NULL
250	NULL
U/ml	NULL
and	NULL
then	NULL
Sendai	NULL
virus	NULL
infection	NULL
at	NULL
1,000	NULL
hemag-glutination	NULL
units	NULL
(	NULL
HAU	NULL
)	NULL
/ml	NULL
(	NULL
Sendai	NULL
virus	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Kari	NULL
Cantell	NULL
)	NULL
.	NULL

PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
induced	NULL
24	NULL
h	NULL
later	NULL
and	NULL
harvested	NULL
36	NULL
h	NULL
following	NULL
transfection	NULL
,	NULL
protein	NULL
was	NULL
collected	NULL
,	NULL
and	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
.	NULL

The	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
constructs	NULL
[	NULL
HIV-LTR	NULL
,	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
,	NULL
5	NULL
'	NULL
«	NULL
B	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
HIV	NULL
mut	NULL
]	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
plasmids	NULL
were	NULL
produced	NULL
by	NULL
subcloning	NULL
different	NULL
NF-	NULL
«	NULL
B	NULL
genes	NULL
into	NULL
the	NULL
SVK3	NULL
vector	NULL
:	NULL
(	NULL
i	NULL
)	NULL
for	NULL
NFKBI1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
a	NULL
1,381-bp	NULL
EcoRI-Rsal	NULL
fragment	NULL
from	NULL
KBF-1	NULL
(	NULL
32	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
EcoRI-Smal	NULL
site	NULL
of	NULL
SVK3	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
for	NULL
AReIA	NULL
(	NULL
p65A	NULL
)	NULL
,	NULL
a	NULL
2,572-bp	NULL
Xbal-Xhol	NULL
fragment	NULL
from	NULL
plasmid	NULL
BL-SK	NULL
(	NULL
58	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
BamHI-Xhol	NULL
site	NULL
of	NULL
SVK3	NULL
;	NULL
(	NULL
iii	NULL
)	NULL
for	NULL
c-re/	NULL
,	NULL
a	NULL
2,340-bp	NULL
EcoRI	NULL
fragment	NULL
of	NULL
c-rel	NULL
cDNA	NULL
(	NULL
11	NULL
)	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
SVK3	NULL
EcoRI	NULL
site	NULL
;	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
for	NULL
IxBa	NULL
,	NULL
a	NULL
1,190-bp	NULL
EcoRI	NULL
fragment	NULL
from	NULL
pGEX-2T	NULL
(	NULL
see	NULL
below	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
SVK3	NULL
.	NULL

The	NULL
CMIN-p65	NULL
vector	NULL
(	NULL
58	NULL
)	NULL
was	NULL
used	NULL
to	NULL
express	NULL
the	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
subunit	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
80	NULL
pug	NULL
of	NULL
protein	NULL
assayed	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
as	NULL
described	NULL
by	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
acetylation	NULL
was	NULL
determined	NULL
,	NULL
and	NULL
the	NULL
relative	NULL
inducibility	NULL
was	NULL
obtained	NULL
by	NULL
dividing	NULL
the	NULL
percent	NULL
conversion	NULL
of	NULL
treated	NULL
samples	NULL
by	NULL
that	NULL
of	NULL
untreated	NULL
samples	NULL
.	NULL

Expression	NULL
and	NULL
purification	NULL
of	NULL
recombinant	NULL
proteins	NULL
.	NULL

The	NULL
cDNA	NULL
clone	NULL
encoding	NULL
p105	NULL
was	NULL
obtained	NULL
from	NULL
A.	NULL
Israel	NULL
,	NULL
and	NULL
the	NULL
region	NULL
corresponding	NULL
to	NULL
p50	NULL
nucleotides	NULL
211	NULL
to	NULL
1687	NULL
(	NULL
encoding	NULL
amino	NULL
acids	NULL
10	NULL
to	NULL
502	NULL
of	NULL
p105	NULL
)	NULL
(	NULL
32	NULL
)	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
pGEX-3X	NULL
expression	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
encoding	NULL
IxBa/MAD-3	NULL
was	NULL
obtained	NULL
by	NULL
reverse	NULL
transcriptase-polymerase	NULL
chain	NULL
reaction	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
from	NULL
Jurkat	NULL
cells	NULL
with	NULL
specific	NULL
primers	NULL
corresponding	NULL
to	NULL
nucleotides	NULL
81	NULL
to	NULL
99	NULL
(	NULL
5-ACGTGAATTCAGCTGGTC	NULL
CGCGCC-3	NULL
'	NULL
)	NULL
and	NULL
1151	NULL
to	NULL
1171	NULL
(	NULL
5'-ATATAGGTGTGACGT	NULL
GTGACCTTAAG-3	NULL
'	NULL
)	NULL
,	NULL
which	NULL
encompassed	NULL
the	NULL
entire	NULL
coding	NULL
region	NULL
of	NULL
MAD-3	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
5	NULL
'	NULL
end	NULL
of	NULL
each	NULL
oligonucleotide	NULL
primer	NULL
contained	NULL
an	NULL
EcoRI	NULL
site	NULL
used	NULL
for	NULL
ligation	NULL
of	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction-amplified	NULL
cDNA	NULL
into	NULL
the	NULL
pGEX-2T	NULL
expression	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

Both	NULL
fusion	NULL
proteins	NULL
were	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
(	NULL
DHSa	NULL
;	NULL
GIBCO/	NULL
BRL	NULL
)	NULL
following	NULL
3	NULL
h	NULL
of	NULL
induction	NULL
with	NULL
1	NULL
mM	NULL
isopropyl-B-D-	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
thiogalactopyranoside	NULL
(	NULL
IPTG	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
at	NULL
30°C	NULL
.	NULL

Protein	NULL
was	NULL
isolated	NULL
following	NULL
bacterial	NULL
lysis	NULL
by	NULL
six	NULL
30-s	NULL
cycles	NULL
of	NULL
sonication	NULL
in	NULL
lysis	NULL
buffer	NULL
:	NULL
20	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
mM	NULL
dithio-threitol	NULL
.	NULL

After	NULL
ammonium	NULL
sulfate	NULL
precipitation	NULL
(	NULL
30	NULL
%	NULL
satura-tion	NULL
)	NULL
,	NULL
proteins	NULL
were	NULL
resolubilized	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
incubated	NULL
with	NULL
glutathione-agarose	NULL
beads	NULL
(	NULL
Pharmacia	NULL
)	NULL
for	NULL
20	NULL
min	NULL
.	NULL

After	NULL
a	NULL
rinse	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
fusion	NULL
proteins	NULL
were	NULL
enzymatically	NULL
cleaved	NULL
as	NULL
follows	NULL
:	NULL
p50	NULL
,	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-150	NULL
mM	NULL
NaCl-1	NULL
mM	NULL
CaCl	NULL
;	NULL
-factor	NULL
Xa	NULL
(	NULL
Boehringer	NULL
GmbH	NULL
,	NULL
Mannheim	NULL
,	NULL
Ger-many	NULL
)	NULL
;	NULL
and	NULL
IxBa	NULL
,	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-150	NULL
mM	NULL
NaCl-2.5	NULL
mM	NULL
CaCl	NULL
,	NULL
;	NULL
-thrombin	NULL
(	NULL
Sigma	NULL
)	NULL
for	NULL
3	NULL
to	NULL
4	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
final	NULL
cleaved	NULL
protein	NULL
products	NULL
were	NULL
eluted	NULL
from	NULL
the	NULL
beads	NULL
with	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-150	NULL
mM	NULL
NaCl	NULL
and	NULL
stored	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
and	NULL
protease	NULL
inhibitors	NULL
.	NULL

WCE	NULL
preparations	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
(	NULL
WCE	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
untreated	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
or	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
25	NULL
ng/ml	NULL
for	NULL
4	NULL
or	NULL
16	NULL
h	NULL
)	NULL
or	NULL
TNF-a	NULL
(	NULL
100	NULL
U/ml	NULL
for	NULL
4	NULL
or	NULL
16	NULL
h	NULL
)	NULL
or	NULL
primed	NULL
with	NULL
IFN-a2	NULL
(	NULL
250	NULL
IU/ml	NULL
for	NULL
4	NULL
h	NULL
)	NULL
and	NULL
infected	NULL
with	NULL
Sendai	NULL
virus	NULL
(	NULL
1,000	NULL
HAU/ml	NULL
for	NULL
6	NULL
h	NULL
)	NULL
.	NULL

Procedures	NULL
for	NULL
extract	NULL
preparation	NULL
were	NULL
those	NULL
described	NULL
previously	NULL
(	NULL
35	NULL
)	NULL
.	NULL

EMSA	NULL
.	NULL

Cell	NULL
extracts	NULL
(	NULL
2.5	NULL
to	NULL
5.0	NULL
ug	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
nonspecific	NULL
DNA	NULL
competitor	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
5	NULL
ug	NULL
;	NULL
Pharmacia	NULL
)	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
15	NULL
to	NULL
20	NULL
ul	NULL
of	NULL
WCE	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Binding	NULL
activity	NULL
was	NULL
assessed	NULL
with	NULL
0.2	NULL
ng	NULL
of	NULL
*°P-end-labelled	NULL
probes	NULL
that	NULL
corresponded	NULL
to	NULL
the	NULL
PRDII	NULL
domain	NULL
of	NULL
the	NULL
IFN-B	NULL
promoter	NULL
(	NULL
5-GGGAAATTCCGGGAAATTCC-3	NULL
'	NULL
)	NULL
,	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
and	NULL
a	NULL
nonspecific	NULL
AT-rich	NULL
oligonucleotide	NULL
(	NULL
5'-AAATTTAA	NULL
ATITAAATTTAAATTT-3	NULL
'	NULL
)	NULL
and	NULL
that	NULL
were	NULL
incubated	NULL
with	NULL
extracts	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
then	NULL
separated	NULL
on	NULL
a	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
60:1	NULL
cross-link	NULL
)	NULL
with	NULL
Tris-glycine	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
195	NULL
mM	NULL
glycine	NULL
[	NULL
pH	NULL
8.5	NULL
]	NULL
)	NULL
.	NULL

In	NULL
the	NULL
competition	NULL
analysis	NULL
,	NULL
a	NULL
125	NULL
M	NULL
excess	NULL
of	NULL
unlabelled	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
WCE	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

For	NULL
examination	NULL
of	NULL
the	NULL
individual	NULL
proteins	NULL
present	NULL
in	NULL
the	NULL
complex	NULL
,	NULL
polyclonal	NULL
subunit-specific	NULL
antisera	NULL
against	NULL
p50	NULL
or	NULL
p105	NULL
(	NULL
antiserum	NULL
1141	NULL
,	NULL
N-terminus	NULL
specific	NULL
)	NULL
(	NULL
51	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
antiserum	NULL
1226	NULL
,	NULL
C-terminus	NULL
specific	NULL
)	NULL
(	NULL
51	NULL
)	NULL
,	NULL
c-rel	NULL
(	NULL
antiserum	NULL
265	NULL
,	NULL
C-terminus	NULL
specific	NULL
)	NULL
(	NULL
11	NULL
)	NULL
,	NULL
and	NULL
p52	NULL
or	NULL
p100	NULL
(	NULL
antiserum	NULL
1267	NULL
,	NULL
N-terminus	NULL
specific	NULL
)	NULL
were	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

Antisera	NULL
(	NULL
1:10	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
WCE	NULL
(	NULL
2.5	NULL
pg	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
a	NULL
specific	NULL
competitor	NULL
peptide	NULL
(	NULL
0.1	NULL
pug/pl	NULL
)	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
radiolabelled	NULL
probe	NULL
as	NULL
described	NULL
for	NULL
the	NULL
EMSA	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
RelA	NULL
and	NULL
IxBa	NULL
.	NULL

PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
resuspended	NULL
in	NULL
methionine-free	NULL
RPMI	NULL
1640	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
labelled	NULL
for	NULL
3	NULL
h	NULL
with	NULL
0.5	NULL
mCi	NULL
of	NULL
Trans*°S	NULL
label	NULL
(	NULL
ICN	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Preparation	NULL
of	NULL
cell	NULL
lysates	NULL
,	NULL
preclearing	NULL
with	NULL
normal	NULL
rabbit	NULL
serum	NULL
,	NULL
and	NULL
immunoprecipitation	NULL
with	NULL
specific	NULL
antibodies	NULL
were	NULL
carried	NULL
out	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
51	NULL
)	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
was	NULL
performed	NULL
in	NULL
situ	NULL
with	NULL
a	NULL
bromodeoxyuridine	NULL
(	NULL
BrdU	NULL
)	NULL
-substi-tuted	NULL
*°P-labelled	NULL
P2	NULL
probe	NULL
in	NULL
a	NULL
standard	NULL
mobility	NULL
shift	NULL
analysis	NULL
,	NULL
scaled	NULL
up	NULL
twofold	NULL
and	NULL
then	NULL
continued	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Tryptic	NULL
digestion	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

Tryptic	NULL
digestion	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
recombinant	NULL
p50	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
or	NULL
WCE	NULL
(	NULL
5	NULL
pg	NULL
)	NULL
in	NULL
10	NULL
ug	NULL
of	NULL
tolylsulfonyl	NULL
phenylalanyl	NULL
chloro-	NULL
INDUCTION	NULL
OF	NULL
NF-	NULL
«	NULL
B	NULL
ACTIVITY	NULL
BY	NULL
VIRUS	NULL
INFECTION	NULL
5237	NULL
P2	NULL
probe	NULL
Treatment	NULL
:	NULL
CP	NULL
go	NULL
CP	NULL
.o	NULL
QQV	NULL
«	NULL
V\	NULL
«	NULL
\6	NULL
Q	NULL
“	NULL
?	NULL

«	NULL
Q	NULL
«	NULL
9	NULL
?	NULL

Bey	NULL
|	NULL
1	NULL
@	NULL
§	NULL
ca	NULL
_j	NULL
.	NULL

4	NULL
&	NULL
509	NULL
s	NULL
;	NULL
|	NULL
PLB-	NULL
985	NULL
PLB-IIIB	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
activities	NULL
following	NULL
PMA	NULL
,	NULL
TNF-a	NULL
,	NULL
or	NULL
virus	NULL
induction	NULL
.	NULL

A	NULL
mobility	NULL
shift	NULL
analysis	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
P2	NULL
probe	NULL
was	NULL
performed	NULL
with	NULL
extracts	NULL
(	NULL
5	NULL
g	NULL
)	NULL
from	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
cells	NULL
;	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
16	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
IFN	NULL
and	NULL
Sendai	NULL
virus	NULL
for	NULL
6	NULL
h	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
TNF-a	NULL
for	NULL
16	NULL
h	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Binding	NULL
activities	NULL
corresponding	NULL
to	NULL
nonspecific	NULL
binding	NULL
(	NULL
ns	NULL
)	NULL
and	NULL
complex	NULL
A	NULL
(	NULL
A	NULL
)	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
arrows	NULL
,	NULL
and	NULL
that	NULL
corresponding	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
kB	NULL
)	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
bracket	NULL
.	NULL

methyl	NULL
ketone	NULL
(	NULL
TPCK	NULL
)	NULL
-trypsin	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
,	NULL
4	NULL
,	NULL
15	NULL
,	NULL
and	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
as	NULL
described	NULL
by	NULL
Bacuerle	NULL
and	NULL
Baltimore	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Digestion	NULL
was	NULL
stopped	NULL
with	NULL
a	NULL
10-fold	NULL
molar	NULL
excess	NULL
of	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
and	NULL
a	NULL
mobility	NULL
shift	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
digested	NULL
extracts	NULL
.	NULL

RESULTS	NULL
Virus	NULL
infection	NULL
induces	NULL
unique	NULL
NF-	NULL
«	NULL
B	NULL
subunit	NULL
combina-tions	NULL
.	NULL

Tandem	NULL
repeats	NULL
of	NULL
two	NULL
different	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
(	NULL
the	NULL
PRDII	NULL
domain	NULL
of	NULL
IFN-B	NULL
and	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
)	NULL
were	NULL
used	NULL
in	NULL
mobility	NULL
shift	NULL
analyses	NULL
to	NULL
assess	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
extracts	NULL
from	NULL
uninfected	NULL
PLB-985	NULL
cells	NULL
or	NULL
PLB-985	NULL
cells	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
PLB-IIIB	NULL
)	NULL
.	NULL

With	NULL
the	NULL
P2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
PLB-985	NULL
cells	NULL
had	NULL
almost	NULL
no	NULL
detectable	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
but	NULL
following	NULL
treatment	NULL
with	NULL
PMA	NULL
or	NULL
TNF-a	NULL
for	NULL
4	NULL
h	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
were	NULL
induced	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
;	NULL
Sendai	NULL
virus	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
for	NULL
6	NULL
h	NULL
also	NULL
induced	NULL
an	NULL
complex	NULL
with	NULL
a	NULL
slightly	NULL
higher	NULL
mobility	NULL
(	NULL
complex	NULL
A	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
extracts	NULL
from	NULL
chronically	NULL
HIV-l-infected	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
complex	NULL
A	NULL
was	NULL
constitutively	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
;	NULL
treatment	NULL
of	NULL
PLB-IIIB	NULL
cells	NULL
with	NULL
PMA	NULL
or	NULL
coinfection	NULL
with	NULL
Sendai	NULL
virus	NULL
increased	NULL
complex	NULL
A	NULL
formation	NULL
two-	NULL
to	NULL
threefold	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
these	NULL
complexes	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
was	NULL
demonstrated	NULL
previously	NULL
in	NULL
competition	NULL
and	NULL
binding	NULL
site	NULL
mutagenesis	NULL
studies	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Complex	NULL
A	NULL
was	NULL
also	NULL
detected	NULL
within	NULL
5	NULL
days	NULL
of	NULL
de	NULL
novo	NULL
HIV-1	NULL
infection	NULL
in	NULL
PLB-985	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
55	NULL
;	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
distinct	NULL
NF-	NULL
«	NULL
B-related	NULL
activities	NULL
observed	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
were	NULL
induced	NULL
not	NULL
only	NULL
by	NULL
chronic	NULL
HIV-1	NULL
infection	NULL
but	NULL
also	NULL
by	NULL
acute	NULL
Sendai	NULL
virus	NULL
infection	NULL
.	NULL

RelA	NULL
(	NULL
p65	NULL
)	NULL
binding	NULL
activity	NULL
is	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
viral	NULL
5238	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
P2	NULL
probe	NULL
antisera	NULL
pre	NULL
«	NULL
p50	NULL
__	NULL
oRel	NULL
A	NULL
_	NULL
ac-rel	NULL
«	NULL
p52	NULL
peptide	NULL
-	NULL
-+	NULL
«	NULL
lg	NULL
20	NULL
%	NULL
UC	NULL
.	NULL

o	NULL
competitor	NULL
#	NULL
#	NULL
*b	NULL
PLB-985	NULL
PMA	NULL
16	NULL
hr	NULL
C	NULL
HIV	NULL
probe	NULL
antisera	NULL
-	NULL
«	NULL
p50	NULL
__	NULL
«	NULL
Rel	NULL
A	NULL
-	NULL
p50	NULL
aRelAI	NULL
I	NULL
T	NULL
1	NULL
I	NULL
I	NULL
peptide	NULL
*	NULL
c	NULL
``	NULL
4	NULL
``	NULL
a	NULL
-	NULL
£0	NULL
&	NULL
0s	NULL
0	NULL
%	NULL
competitor	NULL
121.72	NULL
%	NULL
``	NULL
``	NULL
a	NULL
PLB-985	NULL
PMA	NULL
16	NULL
hr	NULL
6	NULL
j	NULL
j	NULL
6	NULL
7	NULL
$	NULL
2	NULL
10	NULL
;	NULL
PLB-985	NULL
IFN/Sendali	NULL
infection	NULL
.	NULL

For	NULL
identification	NULL
of	NULL
the	NULL
individual	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
associated	NULL
with	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
,	NULL
antisera	NULL
specific	NULL
for	NULL
different	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
,	NULL
NFKB1	NULL
(	NULL
p105	NULL
and	NULL
p50	NULL
)	NULL
,	NULL
NFKB2	NULL
(	NULL
p100	NULL
and	NULL
p52	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
and	NULL
c-rel	NULL
,	NULL
were	NULL
preincubated	NULL
with	NULL
PLB	NULL
cellular	NULL
extracts	NULL
,	NULL
and	NULL
the	NULL
products	NULL
were	NULL
analyzed	NULL
by	NULL
an	NULL
EMSA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
extracts	NULL
from	NULL
PMA-treated	NULL
PLB-985	NULL
cells	NULL
,	NULL
the	NULL
disappearance	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-specific	NULL
complex	NULL
following	NULL
preincubation	NULL
with	NULL
the	NULL
N-termi-nus-reactive	NULL
anti-p105	NULL
or	NULL
anti-p50	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
J.	NULL
Viror	NULL
.	NULL

B	NULL
P2	NULL
probe	NULL
antisera	NULL
pre	NULL
_ap50	NULL
_	NULL
aRel	NULL
A	NULL
_ac-rel	NULL
p52	NULL
peptide	NULL
=	NULL
-	NULL
es	NULL
o	NULL
g	NULL
e	NULL
o	NULL
hag	NULL
sty	NULL
competitor	NULL
#	NULL
#	NULL
Shoah	NULL
bs	NULL
dou	NULL
ah	NULL
but	NULL
tab	NULL
tus	NULL
th	NULL
tub	NULL
deh	NULL
ub	NULL
(	NULL
h	NULL
--	NULL
»	NULL
5	NULL
6	NULL
7	NULL
8	NULL
PLB-985	NULL
IFN/Sendali	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Identification	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
subunits	NULL
.	NULL

WCE	NULL
(	NULL
2.5	NULL
ug	NULL
)	NULL
from	NULL
PMA-treated	NULL
PLB-985	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
or	NULL
Sendai	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
NF-	NULL
«	NULL
B-specific	NULL
antisera	NULL
(	NULL
indicated	NULL
above	NULL
the	NULL
lanes	NULL
)	NULL
for	NULL
10	NULL
min	NULL
and	NULL
then	NULL
allowed	NULL
to	NULL
interact	NULL
with	NULL
a	NULL
*°P-labelled	NULL
P2	NULL
probe	NULL
under	NULL
standard	NULL
EMSA	NULL
conditions	NULL
.	NULL

Antisera	NULL
specific	NULL
for	NULL
N-terminal	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
or	NULL
p105	NULL
(	NULL
1141	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
C-terminal	NULL
RelA	NULL
(	NULL
1226	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
C-terminal	NULL
c-re/	NULL
(	NULL
265	NULL
)	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
,	NULL
and	NULL
N-terminal	NULL
pS2	NULL
or	NULL
lyt-10	NULL
(	NULL
1267	NULL
)	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
were	NULL
used	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
antibody-protein	NULL
complex	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
peptide	NULL
as	NULL
competitor	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Similar	NULL
analyses	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
HIV-1	NULL
probe	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
PMA-treated	NULL
PLB-985	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
and	NULL
IFN-treated	NULL
and	NULL
Sendai	NULL
virus-infected	NULL
cells	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
10	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
antisera	NULL
to	NULL
p50	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
and	NULL
RelA	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

was	NULL
accompanied	NULL
by	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
shifted	NULL
slowly	NULL
migrating	NULL
complex	NULL
;	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
peptide	NULL
used	NULL
for	NULL
antibody	NULL
production	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
shifted	NULL
complex	NULL
,	NULL
thus	NULL
confirming	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

No	NULL
shifted	NULL
complex	NULL
was	NULL
obtained	NULL
with	NULL
antisera	NULL
to	NULL
RelA	NULL
or	NULL
other	NULL
subunits	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
;	NULL
the	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
extracts	NULL
from	NULL
TNF-	NULL
«	NULL
-treated	NULL
PLB-985	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
most	NULL
lanes	NULL
,	NULL
a	NULL
weak	NULL
nonspecific	NULL
shifted	NULL
band	NULL
that	NULL
was	NULL
also	NULL
seen	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
that	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
specific	NULL
peptides	NULL
used	NULL
to	NULL
prepare	NULL
the	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
was	NULL
observed	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
shifted	NULL
complexes	NULL
corresponding	NULL
to	NULL
both	NULL
p50	NULL
and	NULL
RelA	NULL
were	NULL
detected	NULL
in	NULL
extracts	NULL
from	NULL
Sendai	NULL
virus-infected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
;	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
p50	NULL
or	NULL
RelA	NULL
peptide	NULL
to	NULL
the	NULL
reactions	NULL
completely	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
shifted	NULL
antibody-protein-DNA	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

No	NULL
evidence	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
INDUCTION	NULL
OF	NULL
NF-	NULL
«	NULL
B	NULL
ACTIVITY	NULL
BY	NULL
VIRUS	NULL
INFECTION	NULL
5239	NULL
A	NULL
B	NULL
Sendai	NULL
PLB-985	NULL
PLB-IIB	NULL
Uninfected	NULL
infected	NULL
PL	NULL
IxBa	NULL
IxBa	NULL
PI	NULL
IxBo	NULL
.	NULL

IxBo	NULL
.	NULL

1st	NULL
antibody	NULL
PI	NULL
RelA	NULL
PI	NULL
RelA	NULL
IxBo	NULL
RelA	NULL
p50	NULL
lyt10	NULL
PI	NULL
IxBO	NULL
RelA	NULL
p50	NULL
lyt-10	NULL
PI	NULL
2nd	NULL
antibody	NULL
[	NULL
West	NULL
|	NULL
...	NULL
.	NULL

cumin	NULL
97	NULL
--	NULL
97	NULL
2	NULL
4	NULL
69	NULL
-	NULL
Hus	NULL
La-	NULL
(	NULL
79	NULL
;	NULL
Sige	NULL
46	NULL
pec	NULL
yullgeili	NULL
g	NULL
``	NULL
+5	NULL
§	NULL
$	NULL
10	NULL
``	NULL
112	NULL
13°	NULL
14	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
RelA	NULL
and	NULL
IxBa	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Immunoprecipitation	NULL
of	NULL
a	NULL
virus-inducible	NULL
40-kDa	NULL
protein	NULL
by	NULL
anti-RelA	NULL
antiserum	NULL
.	NULL

Cell	NULL
lysates	NULL
from	NULL
PLB-985	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
Sendai	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
and	NULL
with	NULL
anti-RelA	NULL
antiserum	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

PLB-985	NULL
cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
Sendai	NULL
virus	NULL
(	NULL
100	NULL
HAU/m	NULL
!	NULL
)	NULL

for	NULL
2	NULL
h.	NULL
Cells	NULL
were	NULL
labelled	NULL
for	NULL
3	NULL
h	NULL
in	NULL
methionine-free	NULL
RPMI	NULL
1640	NULL
containing	NULL
0.5	NULL
mCi	NULL
of	NULL
Trans*	NULL
``	NULL
$	NULL
label	NULL
per	NULL
ml	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
labelling	NULL
,	NULL
PLB-985	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
;	NULL
after	NULL
a	NULL
3-h	NULL
chase	NULL
,	NULL
proteins	NULL
were	NULL
extracted	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
preimmune	NULL
(	NULL
PI	NULL
)	NULL
serum	NULL
and	NULL
anti-RelA	NULL
antiserum	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Coprecipitation	NULL
of	NULL
RelA	NULL
with	NULL
IxBa	NULL
.	NULL

Extracts	NULL
from	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
cells	NULL
were	NULL
labelled	NULL
for	NULL
3	NULL
h	NULL
in	NULL
methionine-free	NULL
RPMI	NULL
1640	NULL
;	NULL
proteins	NULL
were	NULL
extracted	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
8	NULL
)	NULL
and	NULL
with	NULL
anti-I	NULL
«	NULL
Ba	NULL
antiserum	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
9	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
PLB-985	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
7	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
10	NULL
to	NULL
14	NULL
)	NULL
cells	NULL
were	NULL
also	NULL
immunoprecipitated	NULL
with	NULL
anti-IxBa	NULL
antiserum	NULL
,	NULL
and	NULL
the	NULL
precipitates	NULL
were	NULL
collected	NULL
on	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
and	NULL
extensively	NULL
washed	NULL
.	NULL

Following	NULL
boiling	NULL
in	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-0.5	NULL
%	NULL
B-mercaptoethanol	NULL
,	NULL
the	NULL
initial	NULL
precipitates	NULL
were	NULL
reprecipitated	NULL
with	NULL
antisera	NULL
to	NULL
IxBa	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
10	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
11	NULL
)	NULL
,	NULL
NFKBI1	NULL
(	NULL
p105	NULL
or	NULL
p50	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
12	NULL
)	NULL
,	NULL
and	NULL
NFKB2	NULL
(	NULL
lyt-10	NULL
,	NULL
p100	NULL
,	NULL
or	NULL
p52	NULL
)	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
13	NULL
)	NULL
and	NULL
with	NULL
preimmune	NULL
(	NULL
PI	NULL
)	NULL
serum	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
14	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
(	NULL
in	NULL
kilodaltons	NULL
)	NULL
;	NULL
the	NULL
arrows	NULL
indicate	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
IxBa	NULL
.	NULL

c-rel	NULL
or	NULL
NFKB2	NULL
(	NULL
p100	NULL
or	NULL
p52	NULL
)	NULL
protein	NULL
in	NULL
complex	NULL
formation	NULL
was	NULL
obtained	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
shifted	NULL
complexes	NULL
corresponding	NULL
to	NULL
both	NULL
p50	NULL
and	NULL
RelA	NULL
subunits	NULL
were	NULL
found	NULL
in	NULL
extracts	NULL
from	NULL
HIV-1-infected	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
myeloblastic	NULL
PLB-985	NULL
cells	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
RelA	NULL
DNA	NULL
binding	NULL
is	NULL
specifically	NULL
induced	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
either	NULL
acute	NULL
Sendai	NULL
virus	NULL
infection	NULL
or	NULL
chronic	NULL
HIV-1	NULL
infection	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-NFKB1	NULL
or	NULL
anti-RelA	NULL
antiserum	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
complete	NULL
disappearance	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
,	NULL
even	NULL
with	NULL
titration	NULL
of	NULL
the	NULL
antiserum	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
DNA	NULL
binding	NULL
proteins	NULL
unrelated	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
be	NULL
present	NULL
in	NULL
the	NULL
complex	NULL
.	NULL

When	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
probe	NULL
was	NULL
used	NULL
,	NULL
anti-p50	NULL
completely	NULL
inhibited	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
in	NULL
both	NULL
PMA-and	NULL
Sendai	NULL
virus-induced	NULL
cell	NULL
extracts	NULL
and	NULL
resulted	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
shifted	NULL
protein-DNA	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
the	NULL
p50	NULL
peptide	NULL
used	NULL
to	NULL
produce	NULL
the	NULL
antiserum	NULL
completely	NULL
blocked	NULL
the	NULL
shift	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
RelA	NULL
DNA	NULL
binding	NULL
was	NULL
stimulated	NULL
only	NULL
in	NULL
virus-infected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Anti-ReIA	NULL
antiserum	NULL
resulted	NULL
in	NULL
the	NULL
specific	NULL
disappearance	NULL
of	NULL
the	NULL
uppermost	NULL
protein-DNA	NULL
complex	NULL
;	NULL
the	NULL
addition	NULL
of	NULL
RelA	NULL
peptide	NULL
restored	NULL
the	NULL
uppermost	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
upper	NULL
complex	NULL
also	NULL
disappeared	NULL
when	NULL
anti-p50	NULL
antiserum	NULL
was	NULL
included	NULL
in	NULL
the	NULL
reactions	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
this	NULL
complex	NULL
represents	NULL
a	NULL
pS50-RelA	NULL
heterodimer	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
proteins	NULL
associated	NULL
with	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
probe	NULL
were	NULL
mainly	NULL
RelA	NULL
and	NULL
p50	NULL
,	NULL
whereas	NULL
the	NULL
P2	NULL
probe	NULL
interacted	NULL
with	NULL
RelA	NULL
and	NULL
p50	NULL
as	NULL
well	NULL
as	NULL
other	NULL
proteins	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
RelA	NULL
and	NULL
IBa	NULL
.	NULL

The	NULL
relative	NULL
amounts	NULL
of	NULL
RelA	NULL
and	NULL
NFKBI1	NULL
(	NULL
p50	NULL
)	NULL
were	NULL
not	NULL
increased	NULL
in	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
Western	NULL
immunoblot	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
a	NULL
change	NULL
in	NULL
the	NULL
association	NULL
between	NULL
RelA	NULL
and	NULL
IxBa	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
constitutive	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
,	NULL
coim-munoprecipitation	NULL
was	NULL
performed	NULL
with	NULL
extracts	NULL
from	NULL
uninfected	NULL
and	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
and	NULL
with	NULL
anti-RelA	NULL
and	NULL
anti-IxBa	NULL
antisera	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

PLB-985	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
Sendai	NULL
virus	NULL
and	NULL
pulse	NULL
labelled	NULL
with	NULL
[	NULL
*°SJmethionine	NULL
for	NULL
3	NULL
h	NULL
prior	NULL
to	NULL
preparation	NULL
of	NULL
cell	NULL
lysates	NULL
and	NULL
immunoprecipitation	NULL
with	NULL
anti-RelA	NULL
antiserum	NULL
.	NULL

From	NULL
PLB-985	NULL
cells	NULL
,	NULL
a	NULL
protein	NULL
of	NULL
68	NULL
kDa	NULL
was	NULL
specifically	NULL
immunoprecipitated	NULL
by	NULL
anti-RelA	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
;	NULL
from	NULL
5240	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

PLB-985	NULL
PLB-IIIB	NULL
Competitor	NULL
HIV	NULL
P2	NULL
-	NULL
-	NULL
HIV	NULL
P2	NULL
Competitor	NULL
-	NULL
HIV	NULL
P2	NULL
AT	NULL
HIV	NULL
P2	NULL
AT	NULL
/	NULL
116	NULL
2	NULL
116	NULL
-	NULL
100	NULL
se	NULL
“	NULL
ﬂ	NULL
a	NULL
P	NULL
<	NULL
s	NULL
--	NULL
90	NULL
97	NULL
-	NULL
®	NULL
f	NULL
i	NULL
66	NULL
-	NULL
%	NULL
€	NULL
66	NULL
a	NULL
-a-	NULL
50	NULL
#	NULL
B	NULL
--	NULL
-	NULL
40	NULL
45	NULL
h	NULL
45	NULL
29	NULL
1	NULL
2	NULL
3	NULL
4	NULL
§	NULL
6	NULL
UNTREATED	NULL
TNFo	NULL
:	NULL
29	NULL
Lf	NULL
``	NULL
§	NULL
-	NULL
»	NULL
10	NULL
jill	NULL
12	NULL
is	NULL
14	NULL
UNTREATED	NULL
TNFo	NULL
:	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
of	NULL
P2	NULL
binding	NULL
proteins	NULL
.	NULL

A	NULL
mobility	NULL
shift	NULL
analysis	NULL
scaled	NULL
up	NULL
twofold	NULL
was	NULL
performed	NULL
with	NULL
extracts	NULL
from	NULL
untreated	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
,	NULL
untreated	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
,	NULL
TNF-	NULL
«	NULL
-treated	NULL
PLB-985	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
,	NULL
or	NULL
TNF-	NULL
«	NULL
-treated	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
11	NULL
to	NULL
14	NULL
)	NULL
cells	NULL
and	NULL
a	NULL
*°P-end-labelled	NULL
BrdU-substituted	NULL
probe	NULL
.	NULL

The	NULL
resolved	NULL
complexes	NULL
were	NULL
UV	NULL
irradiated	NULL
in	NULL
situ	NULL
and	NULL
excised	NULL
;	NULL
proteins	NULL
cross-linked	NULL
to	NULL
the	NULL
labelled	NULL
probe	NULL
were	NULL
then	NULL
separated	NULL
on	NULL
a	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
P2	NULL
site	NULL
was	NULL
demonstrated	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
12	NULL
)	NULL
,	NULL
P2	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
)	NULL
or	NULL
AT-rich	NULL
(	NULL
lane	NULL
14	NULL
)	NULL
oligonucleotide	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
molecular	NULL
mass	NULL
standards	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
,	NULL
and	NULL
the	NULL
molecular	NULL
masses	NULL
of	NULL
cross-linked	NULL
proteins	NULL
(	NULL
after	NULL
subtraction	NULL
of	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
probe	NULL
)	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
on	NULL
the	NULL
right	NULL
(	NULL
both	NULL
in	NULL
kilodaltons	NULL
)	NULL
.	NULL

Sendai	NULL
virus-infected	NULL
cells	NULL
,	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
the	NULL
68-kDa	NULL
protein	NULL
was	NULL
precipitated	NULL
,	NULL
but	NULL
in	NULL
addition	NULL
,	NULL
a	NULL
40-kDa	NULL
protein	NULL
was	NULL
coprecipitated	NULL
by	NULL
anti-RelA	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
40-kDa	NULL
protein	NULL
was	NULL
independently	NULL
precipitated	NULL
by	NULL
anti-IxBa	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
from	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
anti-RelA	NULL
antiserum	NULL
specifically	NULL
coprecipitated	NULL
a	NULL
RelA-IxBa	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
anti-IkBa	NULL
antiserum	NULL
was	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
complexes	NULL
from	NULL
PLB-985	NULL
or	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
several	NULL
additional	NULL
proteins	NULL
,	NULL
of	NULL
50	NULL
to	NULL
60	NULL
kDa	NULL
,	NULL
were	NULL
precipitated	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
9	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
these	NULL
proteins	NULL
,	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
boiled	NULL
and	NULL
reprecipitated	NULL
either	NULL
with	NULL
IxBa	NULL
or	NULL
different	NULL
NF-KB	NULL
antibodies	NULL
.	NULL

RelA	NULL
was	NULL
the	NULL
only	NULL
NF-	NULL
«	NULL
B-specific	NULL
protein	NULL
coprecipitated	NULL
with	NULL
anti-IxBa	NULL
antiserum	NULL
from	NULL
PLB-985	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
.	NULL

No	NULL
detectable	NULL
RelA	NULL
was	NULL
coprecipitated	NULL
with	NULL
anti-IxBa	NULL
antiserum	NULL
from	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
11	NULL
to	NULL
13	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
a	NULL
portion	NULL
of	NULL
IxBa	NULL
is	NULL
not	NULL
complexed	NULL
with	NULL
RelA	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
and	NULL
that	NULL
the	NULL
rate	NULL
of	NULL
IxBa	NULL
synthesis	NULL
is	NULL
higher	NULL
in	NULL
virus-infected	NULL
than	NULL
uninfected	NULL
cells	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
stability	NULL
or	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
could	NULL
result	NULL
in	NULL
the	NULL
constitutive	NULL
translocation	NULL
of	NULL
a	NULL
fraction	NULL
of	NULL
RelA	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
and	NULL
sequence	NULL
specificity	NULL
of	NULL
P2	NULL
binding	NULL
proteins	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
with	NULL
a	NULL
BrdU-substituted	NULL
DNA	NULL
probe	NULL
was	NULL
used	NULL
to	NULL
identify	NULL
the	NULL
individual	NULL
proteins	NULL
interacting	NULL
with	NULL
P2	NULL
.	NULL

Unstimulated	NULL
cells	NULL
did	NULL
not	NULL
contain	NULL
detectable	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
proteins	NULL
in	NULL
this	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
;	NULL
however	NULL
,	NULL
complexes	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
treatment	NULL
resolved	NULL
into	NULL
two	NULL
major	NULL
proteins	NULL
,	NULL
of	NULL
40	NULL
and	NULL
50	NULL
kDa	NULL
,	NULL
and	NULL
a	NULL
minor	NULL
protein	NULL
,	NULL
of	NULL
70	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
could	NULL
be	NULL
inhibited	NULL
through	NULL
competition	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
either	NULL
P2	NULL
or	NULL
HIV-1	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
DNA	NULL
binding	NULL
complex	NULL
constitutively	NULL
present	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
55	NULL
)	NULL
and	NULL
in	NULL
Sendai	NULL
virus-induced	NULL
PLB-985	NULL
cells	NULL
resolved	NULL
into	NULL
three	NULL
proteins	NULL
,	NULL
of	NULL
70	NULL
,	NULL
90	NULL
,	NULL
and	NULL
100	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
exhibited	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
specificity	NULL
for	NULL
P2	NULL
and	NULL
were	NULL
inhibited	NULL
through	NULL
competition	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
P2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
13	NULL
)	NULL
but	NULL
not	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
12	NULL
)	NULL
.	NULL

The	NULL
70-kDa	NULL
protein	NULL
was	NULL
induced	NULL
by	NULL
TNF-	NULL
«	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
compare	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
,	NULL
and	NULL
its	NULL
binding	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
IxBa	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
70-kDa	NULL
protein	NULL
therefore	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
subunit	NULL
.	NULL

Thus	NULL
,	NULL
distinct	NULL
proteins	NULL
with	NULL
specificity	NULL
for	NULL
the	NULL
P2	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
appear	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
either	NULL
HIV-1	NULL
or	NULL
Sendai	NULL
virus	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
.	NULL

Specific	NULL
binding	NULL
to	NULL
an	NULL
AT-rich	NULL
oligonucleotide	NULL
.	NULL

The	NULL
P2	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
differs	NULL
from	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
NF-KB	NULL
site	NULL
by	NULL
only	NULL
2	NULL
bases	NULL
,	NULL
at	NULL
positions	NULL
5	NULL
and	NULL
6	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
5-bp	NULL
central	NULL
AT	NULL
-rich	NULL
region	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
virus-inducible	NULL
complex	NULL
A	NULL
could	NULL
bind	NULL
to	NULL
such	NULL
an	NULL
AT-rich	NULL
site	NULL
,	NULL
cellular	NULL
extracts	NULL
from	NULL
TNF-	NULL
«	NULL
-induced	NULL
PLB-985	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
and	NULL
PLB-IHIB	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
radiolabelled	NULL
AT	NULL
-rich	NULL
probe	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
with	NULL
competitor	NULL
DNA	NULL
.	NULL

Interestingly	NULL
,	NULL
binding	NULL
to	NULL
the	NULL
AT-rich	NULL
probe	NULL
was	NULL
detected	NULL
only	NULL
in	NULL
virus-infected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
;	NULL
the	NULL
AT	NULL
binding	NULL
activity	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
P2	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
AT-rich	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
oligonucleotide	NULL
but	NULL
not	NULL
HIV-1	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
same	NULL
AT	NULL
binding	NULL
complex	NULL
was	NULL
also	NULL
generated	NULL
in	NULL
extracts	NULL
from	NULL
Sendai	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
determination	NULL
of	NULL
which	NULL
proteins	NULL
were	NULL
involved	NULL
in	NULL
binding	NULL
to	NULL
this	NULL
AT-rich	NULL
region	NULL
,	NULL
competition	NULL
analysis	NULL
revealed	NULL
that	NULL
only	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
could	NULL
be	NULL
specifically	NULL
inhibited	NULL
through	NULL
competition	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
unlabelled	NULL
AT	NULL
-rich	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
14	NULL
)	NULL
.	NULL

This	NULL
unique	NULL
binding	NULL
specificity	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
Competitor	NULL
HIV	NULL
P2	NULL
AT	NULL
HIV	NULL
P2	NULL
AT	NULL
+	NULL
-	NULL
<	NULL
-	NULL
AT	NULL
«	NULL
i	NULL
bg	NULL
ta	NULL
Cast	NULL
--	NULL
ns	NULL
U	NULL
[	NULL
1	NULL
@	NULL
§	NULL
%	NULL
°	NULL
%	NULL
J	NULL
[	NULL
5°	NULL
6	NULL
Of	NULL
&	NULL
|	NULL
PLB-985	NULL
PLB-IIIB	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Analysis	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
an	NULL
AT-rich	NULL
sequence	NULL
.	NULL

Extracts	NULL
from	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
and	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
cells	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
TNF-a	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
*°P-labelled	NULL
AT	NULL
-rich	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
a	NULL
125-fold	NULL
excess	NULL
of	NULL
unlabelled	NULL
HIV-1	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
P2	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
AT-rich	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
oligonucleotide	NULL
as	NULL
a	NULL
competitor	NULL
.	NULL

Both	NULL
the	NULL
nonspecific	NULL
(	NULL
ns	NULL
)	NULL
band	NULL
and	NULL
the	NULL
specific	NULL
AT-rich	NULL
complex	NULL
are	NULL
indicated	NULL
with	NULL
arrows	NULL
.	NULL

species	NULL
distinguishes	NULL
them	NULL
from	NULL
the	NULL
70-kDa	NULL
protein	NULL
.	NULL

Further-more	NULL
,	NULL
the	NULL
virus-induced	NULL
complex	NULL
binding	NULL
to	NULL
AT	NULL
did	NULL
not	NULL
react	NULL
with	NULL
any	NULL
NF-	NULL
«	NULL
B-specific	NULL
antisera	NULL
(	NULL
p105	NULL
or	NULL
p50	NULL
,	NULL
p100	NULL
or	NULL
p52	NULL
,	NULL
RelA	NULL
,	NULL
or	NULL
c-rel	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
rIxBa	NULL
on	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
protein	NULL
complexes	NULL
induced	NULL
by	NULL
TNF-a	NULL
or	NULL
viral	NULL
infection	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
IxBa	NULL
,	NULL
recombinant	NULL
IkBa	NULL
(	NULL
rIxBa	NULL
)	NULL
/MAD-3	NULL
was	NULL
preincubated	NULL
with	NULL
extracts	NULL
from	NULL
PLB-985	NULL
or	NULL
PLB-IIIB	NULL
cells	NULL
before	NULL
binding	NULL
to	NULL
the	NULL
P2	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

rIkBa	NULL
inhibited	NULL
the	NULL
TNF-	NULL
«	NULL
-induced	NULL
NF-kB	NULL
complexes	NULL
in	NULL
PLB-985	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
only	NULL
partially	NULL
decreased	NULL
the	NULL
level	NULL
of	NULL
complex	NULL
A	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
protein-DNA	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
AT-rich	NULL
probe	NULL
and	NULL
extracts	NULL
from	NULL
PLB-IIIB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
also	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
rikBa	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

This	NULL
result	NULL
also	NULL
indicates	NULL
that	NULL
virus-induced	NULL
complex	NULL
A	NULL
was	NULL
not	NULL
regulated	NULL
by	NULL
IxBa	NULL
and	NULL
may	NULL
not	NULL
be	NULL
an	NULL
complex	NULL
.	NULL

.	NULL

Tryptic	NULL
digestion	NULL
analysis	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
P2	NULL
.	NULL

Previous	NULL
studies	NULL
demonstrated	NULL
that	NULL
NF-kB	NULL
p50	NULL
had	NULL
a	NULL
trypsin-resistant	NULL
core	NULL
that	NULL
maintained	NULL
DNA	NULL
binding	NULL
specificity	NULL
(	NULL
3	NULL
)	NULL
.	NULL

To	NULL
eliminate	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
UV	NULL
cross-linked	NULL
90-	NULL
to	NULL
100-kDa	NULL
adducts	NULL
were	NULL
p50	NULL
homodimers	NULL
irreversibly	NULL
bound	NULL
to	NULL
INDUCTION	NULL
OF	NULL
NF-kB	NULL
ACTIVITY	NULL
BY	NULL
VIRUS	NULL
INFECTION	NULL
5241	NULL
P2	NULL
AT	NULL
rlkB	NULL
|	NULL
-	NULL
+	NULL
--	NULL
+	NULL
~	NULL
o	NULL
+	NULL
--	NULL
A	NULL
|	NULL
--	NULL
ns	NULL
1	NULL
2	NULL
|	NULL
[	NULL
3	NULL
4	NULL
§	NULL
_	NULL
8	NULL
PLB-985	NULL
-	NULL
PLB-IIIB	NULL
_	NULL
PLB-IIIB	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
rIxBa	NULL
on	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

WCE	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
from	NULL
TNF-a	NULL
treated	NULL
PLB-985	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
)	NULL
of	NULL
rIxBa	NULL
purified	NULL
from	NULL
E.	NULL
coli	NULL
for	NULL
10	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
**P-end-labelled	NULL
P2	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
or	NULL
AT-rich	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
probe	NULL
and	NULL
analyzed	NULL
by	NULL
mobility	NULL
shift	NULL
analysis	NULL
.	NULL

Nonspecific	NULL
(	NULL
ns	NULL
)	NULL
binding	NULL
and	NULL
complex	NULL
A	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
,	NULL
while	NULL
the	NULL
NF-kB-specific	NULL
complexes	NULL
in	NULL
lane	NULL
1	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
bracket	NULL
.	NULL

the	NULL
probe	NULL
and	NULL
as	NULL
an	NULL
additional	NULL
test	NULL
of	NULL
the	NULL
NF-KB	NULL
relatedness	NULL
of	NULL
the	NULL
AT-rich	NULL
binding	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
,	NULL
tryptic	NULL
digestion	NULL
analysis	NULL
of	NULL
the	NULL
different	NULL
complexes	NULL
was	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Recombinant	NULL
p50	NULL
and	NULL
extracts	NULL
from	NULL
TNF-a	NULL
«	NULL
-treated	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
digested	NULL
with	NULL
trypsin	NULL
for	NULL
1	NULL
to	NULL
30	NULL
min	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
DNA	NULL
binding	NULL
activity	NULL
to	NULL
P2	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
15	NULL
)	NULL
and	NULL
AT-rich	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
16	NULL
to	NULL
20	NULL
)	NULL
probes	NULL
.	NULL

Purified	NULL
recombinant	NULL
p50	NULL
was	NULL
reduced	NULL
to	NULL
a	NULL
trypsin-resistant	NULL
core	NULL
in	NULL
about	NULL
4	NULL
min	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
complexes	NULL
from	NULL
TNF-	NULL
«	NULL
@	NULL
-treated	NULL
PLB-985	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
6	NULL
to	NULL
10	NULL
)	NULL
were	NULL
degraded	NULL
more	NULL
slowly	NULL
but	NULL
also	NULL
generated	NULL
the	NULL
trypsin-resistant	NULL
core	NULL
.	NULL

Interestingly	NULL
,	NULL
complexes	NULL
from	NULL
TNF-	NULL
«	NULL
-treated	NULL
PLB-IIIB	NULL
cells	NULL
had	NULL
trypsin-sensitive	NULL
and	NULL
trypsin-resistant	NULL
components	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
11	NULL
to	NULL
15	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
a	NULL
portion	NULL
of	NULL
these	NULL
complexes	NULL
corresponds	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
a	NULL
portion	NULL
corresponds	NULL
to	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
species	NULL
.	NULL

The	NULL
protein	NULL
complex	NULL
that	NULL
was	NULL
from	NULL
virus-infected	NULL
cells	NULL
and	NULL
that	NULL
specifically	NULL
bound	NULL
to	NULL
AT-rich	NULL
DNA	NULL
was	NULL
completely	NULL
trypsin	NULL
resistant	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
16	NULL
to	NULL
20	NULL
)	NULL
.	NULL

As	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
observed	NULL
in	NULL
chronically	NULL
HIV-l-infected	NULL
PLB-IIIB	NULL
cells	NULL
or	NULL
in	NULL
Sendai	NULL
virus-infected	NULL
PLB-985	NULL
cells	NULL
possessed	NULL
a	NULL
number	NULL
of	NULL
features	NULL
that	NULL
distinguished	NULL
them	NULL
from	NULL
the	NULL
NF-	NULL
«	NULL
B-specific	NULL
complexes	NULL
observed	NULL
in	NULL
TNF-	NULL
«	NULL
-	NULL
or	NULL
PMA-induced	NULL
PLB-985	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
NF-B-dependent	NULL
plasmids	NULL
in	NULL
PLB	NULL
cells	NULL
.	NULL

To	NULL
TABLE	NULL
1	NULL
.	NULL

Summary	NULL
of	NULL
binding	NULL
activities	NULL
in	NULL
PLB-985	NULL
cells	NULL
Phorbol	NULL
ester-	NULL
or	NULL
TNF-	NULL
«	NULL
-induced	NULL
binding	NULL
HIV-	NULL
or	NULL
Sendai	NULL
virus-induced	NULL
binding	NULL
proteins	NULL
Assays	NULL
used	NULL
to	NULL
characterize	NULL
binding	NULL
proteins	NULL
using	NULL
probe	NULL
:	NULL
using	NULL
probe	NULL
:	NULL
actIvi	NULL
Y	NULL
HIV	NULL
enhancer	NULL
P2	NULL
AT	NULL
HIV	NULL
enhancer	NULL
P2	NULL
AT	NULL
UV-cross-linked	NULL
proteins	NULL
(	NULL
kDa	NULL
)	NULL
40	NULL
,	NULL
50°	NULL
40	NULL
,	NULL
50	NULL
None	NULL
-	NULL
``	NULL
70	NULL
,	NULL
90	NULL
,	NULL
100	NULL
90	NULL
,	NULL
100	NULL
Cross-reactivity	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
antisera	NULL
``	NULL
p50	NULL
p50	NULL
None	NULL
p50	NULL
,	NULL
RelA	NULL
p50	NULL
,	NULL
RelA	NULL
None	NULL
ri	NULL
«	NULL
kBo/MAD-3	NULL
inhibition©®	NULL
++	NULL
++	NULL
-	NULL
++	NULL
+/-	NULL
Trypsin	NULL
sensitivity	NULL
``	NULL
ND	NULL
++	NULL
-	NULL
ND	NULL
+/-	NULL
``	NULL
Refer	NULL
to	NULL
reference	NULL
55	NULL
.	NULL

®	NULL
Antisera	NULL
against	NULL
p50	NULL
and	NULL
p105	NULL
,	NULL
pS2	NULL
and	NULL
p100	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
c-re/	NULL
were	NULL
tested	NULL
.	NULL

©	NULL
++	NULL
,	NULL
complete	NULL
;	NULL
+	NULL
,	NULL
partial	NULL
;	NULL
-	NULL
none	NULL
.	NULL

4	NULL
++	NULL
,	NULL
complete	NULL
;	NULL
+	NULL
partial	NULL
;	NULL
-	NULL
resistant	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

5242	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

P2	NULL
probe	NULL
AT	NULL
rich	NULL
probe	NULL
J	NULL
I	NULL
|	NULL
0	NULL
O1	NULL
4	NULL
15	NULL
30	NULL
0	NULL
1	NULL
4	NULL
15	NULL
30	NULL
0	NULL
1	NULL
4	NULL
15	NULL
30	NULL
0	NULL
1	NULL
4	NULL
15	NULL
30	NULL
_	NULL
Digestion	NULL
time	NULL
(	NULL
mins	NULL
)	NULL
*	NULL
Teverererece	NULL
#	NULL
[	NULL
1	NULL
(	NULL
20	NULL
B	NULL
4	NULL
'	NULL
B	NULL
pe	NULL
7B	NULL
o	NULL
10	NULL
|	NULL
11	NULL
12-42	NULL
14	NULL
15	NULL
jie	NULL
17	NULL
18	NULL
»	NULL
19	NULL
'20	NULL
;	NULL
rp50	NULL
PLB-985	NULL
PLB-IIIB	NULL
PLB-IIIB	NULL
TNFo	NULL
4h	NULL
TNFo	NULL
4h	NULL
TNFo	NULL
:	NULL
4h	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Tryptic	NULL
digestion	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
P2	NULL
probe	NULL
.	NULL

Proteins	NULL
binding	NULL
to	NULL
P2	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
15	NULL
)	NULL
or	NULL
to	NULL
AT-rich	NULL
(	NULL
lanes	NULL
16	NULL
to	NULL
20	NULL
)	NULL
sequences	NULL
were	NULL
analyzed	NULL
by	NULL
an	NULL
EMSA	NULL
following	NULL
tryptic	NULL
digestion	NULL
.	NULL

Recombinant	NULL
NF-kB	NULL
p50	NULL
purified	NULL
from	NULL
E.	NULL
coli	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
and	NULL
WCE	NULL
from	NULL
TNF-a	NULL
(	NULL
4-h	NULL
)	NULL
-treated	NULL
PLB-985	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
10	NULL
)	NULL
or	NULL
PLB-IIIB	NULL
(	NULL
lanes	NULL
11	NULL
to	NULL
20	NULL
)	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
tryptic	NULL
digestion	NULL
analysis	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
6	NULL
,	NULL
11	NULL
,	NULL
and	NULL
16	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
TPCK-trypsin	NULL
for	NULL
1	NULL
min	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
7	NULL
,	NULL
12	NULL
,	NULL
and	NULL
17	NULL
)	NULL
,	NULL
for	NULL
4	NULL
min	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
8	NULL
,	NULL
13	NULL
,	NULL
and	NULL
18	NULL
)	NULL
,	NULL
for	NULL
15	NULL
min	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
9	NULL
,	NULL
14	NULL
,	NULL
and	NULL
19	NULL
)	NULL
,	NULL
or	NULL
30	NULL
min	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
10	NULL
,	NULL
15	NULL
,	NULL
and	NULL
20	NULL
)	NULL
,	NULL
and	NULL
then	NULL
digestion	NULL
was	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
10-fold	NULL
molar	NULL
excess	NULL
of	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
.	NULL

demonstrate	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
these	NULL
distinct	NULL
binding	NULL
species	NULL
in	NULL
vivo	NULL
,	NULL
transient	NULL
transfection	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
PLB-985	NULL
cells	NULL
,	NULL
using	NULL
NF-	NULL
«	NULL
B-driven	NULL
constructs	NULL
expressing	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Constructs	NULL
consisted	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
HIV-LTR	NULL
)	NULL
,	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
PRDII/NF-	NULL
«	NULL
B	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
minimal	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
[	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
]	NULL
,	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
[	NULL
5	NULL
'	NULL
«	NULL
B	NULL
(	NULL
3	NULL
)	NULL
]	NULL
,	NULL
and	NULL
a	NULL
mutant	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
HIV	NULL
mut	NULL
)	NULL
(	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Following	NULL
DEAE-dextran-mediated	NULL
transfection	NULL
into	NULL
PLB-985	NULL
cells	NULL
,	NULL
all	NULL
constructs	NULL
had	NULL
a	NULL
low	NULL
level	NULL
of	NULL
activity	NULL
;	NULL
for	NULL
all	NULL
plasmids	NULL
except	NULL
the	NULL
HIV	NULL
mut	NULL
plasmid	NULL
,	NULL
PMA	NULL
treatment	NULL
at	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
resulted	NULL
in	NULL
a	NULL
4-	NULL
to	NULL
12-fold	NULL
inducibility	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
the	NULL
same	NULL
plasmids	NULL
were	NULL
introduced	NULL
into	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
a	NULL
high	NULL
basal	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
HIV-LTR	NULL
,	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
5	NULL
'	NULL
«	NULL
kB	NULL
(	NULL
3	NULL
)	NULL
plasmids	NULL
;	NULL
this	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
not	NULL
increased	NULL
significantly	NULL
by	NULL
PMA	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
high	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
functional	NULL
NF-kB	NULL
binding	NULL
sites	NULL
,	NULL
since	NULL
the	NULL
HIV	NULL
mut	NULL
plasmid	NULL
had	NULL
a	NULL
low	NULL
basal	NULL
level	NULL
of	NULL
activity	NULL
and	NULL
no	NULL
inducible	NULL
activity	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

In	NULL
cotransfection	NULL
experiments	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
overexpression	NULL
of	NULL
individual	NULL
NF-	NULL
«	NULL
B	NULL
subunits-NFKBI1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
RelA	NULL
,	NULL
c-rel	NULL
,	NULL
AReIA	NULL
,	NULL
or	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
RelA	NULL
together-on	NULL
HIV-LTR-or	NULL
5'kB	NULL
(	NULL
3	NULL
)	NULL
-dependent	NULL
gene	NULL
expression	NULL
were	NULL
measured	NULL
in	NULL
a	NULL
Jurkat	NULL
T-cell	NULL
background	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
either	NULL
RelA	NULL
alone	NULL
or	NULL
RelA	NULL
in	NULL
combination	NULL
with	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
stimulated	NULL
the	NULL
HIV-LTR	NULL
,	NULL
5	NULL
'	NULL
«	NULL
B	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
constructs	NULL
but	NULL
did	NULL
not	NULL
stimulate	NULL
the	NULL
HIV	NULL
mut	NULL
construct	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
alterations	NULL
in	NULL
the	NULL
NF-kB	NULL
binding	NULL
activities	NULL
observed	NULL
in	NULL
HIV-l-infected	NULL
cells	NULL
may	NULL
result	NULL
in	NULL
higher	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B-regulated	NULL
gene	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
Two	NULL
distinct	NULL
types	NULL
of	NULL
virus	NULL
infection-one	NULL
an	NULL
acute	NULL
paramyxovirus	NULL
infection	NULL
and	NULL
the	NULL
other	NULL
a	NULL
chronic	NULL
lentivirus	NULL
infection-result	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
multiple	NULL
NF-	NULL
«	NULL
B-related	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

Chronic	NULL
HIV-1	NULL
infection	NULL
sustains	NULL
constitutive	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
myeloid	NULL
model	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

As	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
virus	NULL
infection	NULL
by	NULL
either	NULL
Sendai	NULL
virus	NULL
or	NULL
HIV-1	NULL
induced	NULL
DNA	NULL
binding	NULL
complexes	NULL
consisting	NULL
of	NULL
70-	NULL
,	NULL
90-	NULL
,	NULL
and	NULL
100-kDa	NULL
proteins	NULL
;	NULL
binding	NULL
assays	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
subunit-specific	NULL
antisera	NULL
demonstrated	NULL
that	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
were	NULL
present	NULL
in	NULL
the	NULL
virus-induced	NULL
complexes	NULL
and	NULL
bound	NULL
to	NULL
both	NULL
HIV-1	NULL
enhancer	NULL
and	NULL
PRDII/NF-	NULL
«	NULL
B	NULL
probes	NULL
,	NULL
although	NULL
p50	NULL
was	NULL
only	NULL
weakly	NULL
detected	NULL
by	NULL
cross-linking	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
antibody	NULL
cross-reactivity	NULL
,	NULL
molecular	NULL
weight	NULL
,	NULL
TNF	NULL
inducibility	NULL
and	NULL
inhibition	NULL
by	NULL
rIkBa	NULL
,	NULL
the	NULL
70-kDa	NULL
protein	NULL
corresponds	NULL
to	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
amounts	NULL
of	NULL
RelA	NULL
and	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
proteins	NULL
were	NULL
not	NULL
increased	NULL
in	NULL
virus-infected	NULL
cells	NULL
,	NULL
pulse-chase	NULL
and	NULL
coim-munoprecipitation	NULL
experiments	NULL
were	NULL
undertaken	NULL
to	NULL
examine	NULL
the	NULL
interactions	NULL
between	NULL
RelA	NULL
and	NULL
IxBa	NULL
.	NULL

These	NULL
experiments	NULL
indicated	NULL
that	NULL
Sendai	NULL
virus	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
induced	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
IxBa	NULL
,	NULL
and	NULL
the	NULL
newly	NULL
synthesized	NULL
IxBa	NULL
was	NULL
chased	NULL
into	NULL
a	NULL
complex	NULL
that	NULL
could	NULL
be	NULL
immunoprecipitated	NULL
with	NULL
either	NULL
anti-RelA	NULL
(	NULL
p65	NULL
)	NULL
or	NULL
anti-IxBa	NULL
antiserum	NULL
.	NULL

In	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
anti-RelA	NULL
(	NULL
p65	NULL
)	NULL
antiserum	NULL
immunoprecipitated	NULL
a	NULL
RelA-IxBa	NULL
complex	NULL
,	NULL
whereas	NULL
no	NULL
detectable	NULL
RelA	NULL
was	NULL
coprecipitated	NULL
with	NULL
anti-IxBa	NULL
antiserum	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
PLB-IIIB	NULL
cells	NULL
,	NULL
two	NULL
types	NULL
of	NULL
IxBa	NULL
complexes	NULL
may	NULL
exist-one	NULL
composed	NULL
of	NULL
RelA	NULL
and	NULL
IxBa	NULL
and	NULL
the	NULL
other	NULL
composed	NULL
of	NULL
IxBa	NULL
without	NULL
RelA	NULL
(	NULL
possibly	NULL
complexed	NULL
to	NULL
other	NULL
induced	NULL
cellular	NULL
proteins	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
recently	NULL
by	NULL
Sun	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
10	NULL
C	NULL
0	NULL
©	NULL
6	NULL
6.	NULL
a*	NULL
2	NULL
o	NULL
z	NULL
pal	NULL
HIV	NULL
LTR	NULL
_	NULL
HIV	NULL
mut	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
5'xB	NULL
(	NULL
3	NULL
)	NULL
Relative	NULL
Induction	NULL
3.7	NULL
.15	NULL
12.8	NULL
6.4	NULL
10	NULL
PLB-lIIB	NULL
8	NULL
g	NULL
6	NULL
0	NULL
®	NULL
Bok	NULL
8	NULL
<	NULL
&	NULL
2	NULL
ol	NULL
ZE	NULL
HIV	NULL
LTR	NULL
_	NULL
HIV	NULL
mut	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
5'xB	NULL
(	NULL
3	NULL
)	NULL
Relative	NULL
Induction	NULL
1.4	NULL
1.5	NULL
1.4	NULL
2.0	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B-dependent	NULL
reporter	NULL
constructs	NULL
in	NULL
PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
.	NULL

PLB-985	NULL
and	NULL
PLB-IIIB	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
use	NULL
of	NULL
DEAE-dextran	NULL
with	NULL
8	NULL
ug	NULL
of	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
HIV-1-LTR	NULL
,	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
[	NULL
5'kB	NULL
(	NULL
3	NULL
)	NULL
]	NULL
,	NULL
the	NULL
P2	NULL
domain	NULL
[	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
]	NULL
,	NULL
or	NULL
a	NULL
mutant	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
HIV	NULL
mut	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
25	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
following	NULL
transfection	NULL
and	NULL
then	NULL
harvested	NULL
12	NULL
h	NULL
after	NULL
induction	NULL
.	NULL

Chloramphenicol	NULL
acetylation	NULL
was	NULL
assessed	NULL
with	NULL
80	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
for	NULL
2	NULL
h	NULL
;	NULL
transcriptional	NULL
activity	NULL
is	NULL
represented	NULL
as	NULL
percent	NULL
acetylation	NULL
.	NULL

Symbols	NULL
:	NULL
§	NULL
,	NULL
uninduced	NULL
cells	NULL
;	NULL
II	NULL
,	NULL
PMA-induced	NULL
cells	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
63a	NULL
)	NULL
,	NULL
rapid	NULL
degradation	NULL
of	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
intracellular	NULL
IxBa	NULL
pool	NULL
could	NULL
result	NULL
in	NULL
constitutive	NULL
translocation	NULL
of	NULL
a	NULL
fraction	NULL
of	NULL
RelA	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Nuclear	NULL
RelA	NULL
protein	NULL
could	NULL
in	NULL
turn	NULL
stimulate	NULL
IxBa	NULL
synthesis	NULL
by	NULL
an	NULL
autoregulatory	NULL
mechanism	NULL
(	NULL
63a	NULL
)	NULL
.	NULL

TABLE	NULL
2	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
individual	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
on	NULL
NF-	NULL
«	NULL
B-driven	NULL
promoters	NULL
Inducer	NULL
or	NULL
NF-xB	NULL
Activity	NULL
``	NULL
of	NULL
CAT	NULL
reporter	NULL
construct	NULL
:	NULL
subunit	NULL
HIV-LTR	NULL
_	NULL
5'xB	NULL
(	NULL
3	NULL
)	NULL
_	NULL
HIV	NULL
mut	NULL
P2	NULL
(	NULL
2	NULL
)	NULL
None	NULL
3.3	NULL
(	NULL
1.0	NULL
)	NULL
-	NULL
3.5	NULL
(	NULL
1.0	NULL
)	NULL
-	NULL
0.3	NULL
(	NULL
1.0	NULL
)	NULL
_	NULL
1.4	NULL
(	NULL
1.0	NULL
)	NULL
PMA	NULL
30.1	NULL
(	NULL
9.1	NULL
)	NULL
52.5	NULL
(	NULL
15	NULL
)	NULL
-	NULL
0.5	NULL
(	NULL
1.7	NULL
)	NULL
20.1	NULL
(	NULL
14.3	NULL
)	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
3.1	NULL
(	NULL
0.9	NULL
)	NULL
15.8	NULL
(	NULL
4.5	NULL
)	NULL
0.4	NULL
(	NULL
1.3	NULL
)	NULL
_	NULL
3.9	NULL
(	NULL
2.8	NULL
)	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
6.9	NULL
(	NULL
2.1	NULL
)	NULL
44.8	NULL
(	NULL
12.8	NULL
)	NULL
0.4	NULL
(	NULL
1.3	NULL
)	NULL
25.6	NULL
(	NULL
18.2	NULL
)	NULL
c-rel	NULL
2.0	NULL
(	NULL
0.6	NULL
)	NULL
-	NULL
6.4	NULL
(	NULL
1.8	NULL
)	NULL
-	NULL
0.3	NULL
(	NULL
1.0	NULL
)	NULL
-	NULL
4.6	NULL
(	NULL
3.3	NULL
)	NULL
NFKB1	NULL
+	NULL
RelA	NULL
16.1	NULL
(	NULL
4.9	NULL
)	NULL
74.7	NULL
(	NULL
21.3	NULL
)	NULL
0.4	NULL
(	NULL
1.3	NULL
)	NULL
49.2	NULL
(	NULL
35.1	NULL
)	NULL
AReIA	NULL
1.8	NULL
(	NULL
0.5	NULL
)	NULL
_	NULL
4.3	NULL
(	NULL
1.2	NULL
)	NULL
ND	NULL
1.2	NULL
(	NULL
0.9	NULL
)	NULL
IxBa	NULL
0.8	NULL
(	NULL
0.2	NULL
)	NULL
-	NULL
1.7	NULL
(	NULL
0.5	NULL
)	NULL
ND	NULL
2.3	NULL
(	NULL
1.6	NULL
)	NULL
``	NULL
Data	NULL
are	NULL
reported	NULL
as	NULL
percent	NULL
acetylation	NULL
(	NULL
relative	NULL
induction	NULL
)	NULL
.	NULL

ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

INDUCTION	NULL
OF	NULL
NF-	NULL
«	NULL
B	NULL
ACTIVITY	NULL
BY	NULL
VIRUS	NULL
INFECTION	NULL
5243	NULL
Other	NULL
studies	NULL
have	NULL
demonstrated	NULL
the	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
HIV-1-infected	NULL
U937	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
,	NULL
via	NULL
a	NULL
mechanism	NULL
involving	NULL
increased	NULL
transcription	NULL
and	NULL
processing	NULL
of	NULL
the	NULL
p105	NULL
precursor	NULL
(	NULL
47	NULL
,	NULL
52	NULL
)	NULL
.	NULL

In	NULL
THP-1	NULL
cells	NULL
,	NULL
HIV-1	NULL
infection	NULL
resulted	NULL
in	NULL
two	NULL
populations	NULL
of	NULL
chronically	NULL
infected	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
productively	NULL
infected	NULL
cells	NULL
contained	NULL
increased	NULL
p50-RelA	NULL
heterodimer	NULL
binding	NULL
activity	NULL
,	NULL
whereas	NULL
extracts	NULL
from	NULL
cells	NULL
expressing	NULL
low	NULL
levels	NULL
of	NULL
virus	NULL
(	NULL
restricted	NULL
expression	NULL
)	NULL
displayed	NULL
only	NULL
p50	NULL
homodimer	NULL
binding	NULL
activity	NULL
.	NULL

Increased	NULL
NF-	NULL
«	NULL
B	NULL
p50-RelA	NULL
binding	NULL
activity	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
HIV-1-infected	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
and	NULL
macrophages	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
certain	NULL
level	NULL
of	NULL
myeloid	NULL
maturation	NULL
was	NULL
required	NULL
prior	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
(	NULL
64	NULL
)	NULL
.	NULL

The	NULL
PRDII	NULL
binding	NULL
complex	NULL
(	NULL
A	NULL
)	NULL
identified	NULL
in	NULL
Sendai	NULL
virus-infected	NULL
cells	NULL
and	NULL
in	NULL
HIV-l-infected	NULL
PLB-IIIB	NULL
cells	NULL
was	NULL
not	NULL
completely	NULL
shifted	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
p50	NULL
or	NULL
RelA	NULL
antibody	NULL
or	NULL
other	NULL
antibodies	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
another	NULL
,	NULL
unrelated	NULL
complex	NULL
.	NULL

This	NULL
complex	NULL
appears	NULL
to	NULL
be	NULL
composed	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
,	NULL
which	NULL
possess	NULL
a	NULL
high	NULL
affinity	NULL
for	NULL
binding	NULL
to	NULL
AT-rich	NULL
sequences	NULL
,	NULL
including	NULL
the	NULL
IFN-B	NULL
PRDII	NULL
domain	NULL
.	NULL

Several	NULL
experiments	NULL
illustrate	NULL
the	NULL
lack	NULL
of	NULL
similarity	NULL
between	NULL
these	NULL
proteins	NULL
and	NULL
previously	NULL
characterized	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
.	NULL

First	NULL
,	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
associated	NULL
with	NULL
either	NULL
the	NULL
P2	NULL
or	NULL
the	NULL
AT-rich	NULL
probe	NULL
were	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
rIkBa	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
protein	NULL
complex	NULL
with	NULL
the	NULL
P2	NULL
or	NULL
the	NULL
AT-rich	NULL
probe	NULL
was	NULL
not	NULL
blocked	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
several	NULL
different	NULL
NF-	NULL
«	NULL
B	NULL
subunit-specific	NULL
antisera	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
virus-induced	NULL
90-	NULL
to	NULL
100-kDa	NULL
protein	NULL
complex	NULL
was	NULL
trypsin	NULL
resistant	NULL
,	NULL
whereas	NULL
recombinant	NULL
p50	NULL
or	NULL
p50-RelA	NULL
from	NULL
cell	NULL
extracts	NULL
was	NULL
trypsin	NULL
sensitive	NULL
.	NULL

The	NULL
protein	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
AT	NULL
probe	NULL
was	NULL
also	NULL
trypsin	NULL
resistant	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
unique	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
protein	NULL
complex	NULL
,	NULL
the	NULL
inability	NULL
of	NULL
IxBa	NULL
to	NULL
block	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
the	NULL
trypsin	NULL
resistance	NULL
of	NULL
the	NULL
complex	NULL
,	NULL
these	NULL
proteins	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
NF-KB	NULL
related	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
are	NULL
related	NULL
to	NULL
other	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
AT-rich	NULL
sequences	NULL
or	NULL
to	NULL
the	NULL
chromosome-associated	NULL
HMG	NULL
I/Y	NULL
proteins	NULL
,	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
PRDII	NULL
domain	NULL
(	NULL
65	NULL
)	NULL
.	NULL

HMG	NULL
I/Y	NULL
proteins	NULL
of	NULL
approximately	NULL
15	NULL
kDa	NULL
bind	NULL
to	NULL
the	NULL
minor	NULL
groove	NULL
of	NULL
PRDII	NULL
and	NULL
interact	NULL
with	NULL
the	NULL
central	NULL
AAATT	NULL
sequence	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
major	NULL
groove	NULL
increased	NULL
by	NULL
10-	NULL
to	NULL
20-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
HMG	NULL
I/Y	NULL
and	NULL
resulted	NULL
in	NULL
a	NULL
complex	NULL
of	NULL
retarded	NULL
mobility	NULL
that	NULL
contributed	NULL
to	NULL
PRDII-dependent	NULL
,	NULL
virus-inducible	NULL
expression	NULL
of	NULL
IFN-B	NULL
(	NULL
65	NULL
)	NULL
.	NULL

At	NULL
present	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
represent	NULL
a	NULL
complex	NULL
between	NULL
HMG	NULL
I/Y	NULL
and	NULL
the	NULL
RelA	NULL
subunit	NULL
.	NULL

The	NULL
association	NULL
of	NULL
RelA	NULL
with	NULL
HMG	NULL
I/Y	NULL
may	NULL
be	NULL
highly	NULL
stable	NULL
and	NULL
sufficient	NULL
to	NULL
alter	NULL
the	NULL
biochemical	NULL
characteristics	NULL
of	NULL
the	NULL
protein-DNA	NULL
complex	NULL
.	NULL

However	NULL
,	NULL
mixing	NULL
experiments	NULL
with	NULL
recombinant	NULL
RelA	NULL
and	NULL
HMG	NULL
I	NULL
and	NULL
Y	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
D.	NULL
Thanos	NULL
and	NULL
T.	NULL
Maniatis	NULL
)	NULL
failed	NULL
to	NULL
generate	NULL
complex	NULL
A-like	NULL
binding	NULL
activity	NULL
(	NULL
54a	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Nakayama	NULL
et	NULL
al	NULL
.	NULL

(	NULL
42	NULL
)	NULL
characterized	NULL
a	NULL
high-molecular-weight	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
that	NULL
was	NULL
constitutively	NULL
present	NULL
in	NULL
lymphoid	NULL
cells	NULL
and	NULL
that	NULL
interacted	NULL
with	NULL
the	NULL
IL-6	NULL
«	NULL
B	NULL
motif	NULL
,	NULL
which	NULL
also	NULL
has	NULL
a	NULL
central	NULL
5-bp	NULL
AT-rich	NULL
region	NULL
.	NULL

Although	NULL
the	NULL
sequence	NULL
specificity	NULL
of	NULL
IL-6	NULL
kB	NULL
BFII	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
described	NULL
here	NULL
,	NULL
the	NULL
BFII	NULL
binding	NULL
activity	NULL
was	NULL
partially	NULL
inhibited	NULL
by	NULL
c-rel	NULL
antisera	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Similarly	NULL
Lattion	NULL
et	NULL
al	NULL
.	NULL

(	NULL
36	NULL
)	NULL
characterized	NULL
a	NULL
high-molecular-weight	NULL
lymphoid	NULL
cell-specific	NULL
factor	NULL
,	NULL
NP-TCIHI	NULL
,	NULL
which	NULL
bound	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
B	NULL
site	NULL
but	NULL
was	NULL
distinct	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
several	NULL
criteria	NULL
:	NULL
lack	NULL
of	NULL
5244	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

inhibition	NULL
by	NULL
IxBa	NULL
,	NULL
inability	NULL
to	NULL
be	NULL
stimulated	NULL
by	NULL
deoxy-cholate	NULL
treatment	NULL
,	NULL
distinct	NULL
tryptic	NULL
digestion	NULL
products	NULL
,	NULL
and	NULL
lack	NULL
of	NULL
reactivity	NULL
to	NULL
antisera	NULL
against	NULL
p50	NULL
,	NULL
v-rel	NULL
,	NULL
or	NULL
c-rel	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
this	NULL
factor	NULL
was	NULL
high	NULL
in	NULL
pre-B	NULL
and	NULL
immature	NULL
T	NULL
cells	NULL
and	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
lymphocytic	NULL
development	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
biochemical	NULL
identity	NULL
of	NULL
these	NULL
proteins	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
comparison	NULL
with	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
,	NULL
will	NULL
require	NULL
further	NULL
analysis	NULL
.	NULL

Distinct	NULL
combinations	NULL
of	NULL
NF-KB	NULL
binding	NULL
proteins	NULL
contribute	NULL
to	NULL
differential	NULL
gene	NULL
activation	NULL
(	NULL
5	NULL
,	NULL
28	NULL
,	NULL
33	NULL
,	NULL
35	NULL
,	NULL
48	NULL
,	NULL
68-70	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
experiments	NULL
demonstrated	NULL
that	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
homodimers	NULL
stimulated	NULL
transcription	NULL
from	NULL
a	NULL
template	NULL
controlled	NULL
by	NULL
the	NULL
immunoglobulin	NULL
k	NULL
element	NULL
but	NULL
not	NULL
by	NULL
the	NULL
PRDII	NULL
element	NULL
,	NULL
whereas	NULL
RelA	NULL
homodimers	NULL
or	NULL
NFKB1-RelA	NULL
heterodimers	NULL
stimulated	NULL
in	NULL
vitro	NULL
transcription	NULL
from	NULL
both	NULL
the	NULL
immunoglobulin	NULL
k	NULL
and	NULL
the	NULL
PRDII	NULL
templates	NULL
by	NULL
10-fold	NULL
.	NULL

Conformational	NULL
differences	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
degree	NULL
of	NULL
transcriptional	NULL
activation	NULL
by	NULL
different	NULL
subunit	NULL
combinations	NULL
(	NULL
16	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
those	NULL
of	NULL
cotransfection	NULL
studies	NULL
demonstrating	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
heterodimer	NULL
combinations	NULL
are	NULL
transcriptionally	NULL
more	NULL
potent	NULL
than	NULL
p50	NULL
homodimers	NULL
(	NULL
48	NULL
,	NULL
61	NULL
)	NULL
.	NULL

With	NULL
regard	NULL
to	NULL
HIV-1	NULL
infection	NULL
,	NULL
an	NULL
increase	NULL
in	NULL
transcriptionally	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
complexes	NULL
in	NULL
general	NULL
and	NULL
constitutive	NULL
posttranslational	NULL
induction	NULL
of	NULL
RelA	NULL
in	NULL
particular	NULL
appears	NULL
to	NULL
provide	NULL
an	NULL
intranuclear	NULL
environment	NULL
that	NULL
maintains	NULL
a	NULL
high	NULL
level	NULL
of	NULL
HIV-1	NULL
LTR-mediated	NULL
gene	NULL
expres-sion	NULL
.	NULL

Enhanced	NULL
HIV-1	NULL
replication	NULL
in	NULL
myeloid	NULL
cells	NULL
may	NULL
activate	NULL
other	NULL
NF-	NULL
«	NULL
B-regulated	NULL
cytokine	NULL
genes	NULL
,	NULL
including	NULL
TNF	NULL
,	NULL
IL-1	NULL
,	NULL
IL-2	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
an	NULL
autostimulatory	NULL
effect	NULL
on	NULL
HIV-1	NULL
replication	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
,	NULL
cytokine	NULL
induction	NULL
may	NULL
produce	NULL
a	NULL
range	NULL
of	NULL
pleio-tropic	NULL
effects	NULL
in	NULL
the	NULL
host	NULL
,	NULL
including	NULL
inflammation	NULL
,	NULL
fever	NULL
,	NULL
and	NULL
cachexia	NULL
(	NULL
54	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
activation	NULL
of	NULL
specific	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/re/	NULL
family	NULL
of	NULL
transcription	NULL
proteins	NULL
may	NULL
thus	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Alain	NULL
Israel	NULL
,	NULL
Craig	NULL
Rosen	NULL
,	NULL
and	NULL
Steven	NULL
Ruben	NULL
for	NULL
NF-	NULL
<	NULL
B	NULL
plasmids	NULL
,	NULL
Kari	NULL
Cantell	NULL
for	NULL
Sendai	NULL
virus	NULL
,	NULL
D.	NULL
Thanos	NULL
and	NULL
T.	NULL
Maniatis	NULL
for	NULL
recombinant	NULL
HMG	NULL
I/Y	NULL
proteins	NULL
,	NULL
and	NULL
I.	NULL
Kwan	NULL
,	NULL
N.	NULL
Pepin	NULL
,	NULL
and	NULL
J.	NULL
Garoufalis	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
research	NULL
was	NULL
sponsored	NULL
in	NULL
part	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
under	NULL
contract	NULL
NO1-CO-74101	NULL
with	NULL
ABL	NULL
(	NULL
to	NULL
N.R	NULL
.	NULL
)	NULL

and	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
and	NULL
the	NULL
National	NULL
Health	NULL
Research	NULL
Development	NULL
Program	NULL
,	NULL
Health	NULL
and	NULL
Welfare	NULL
Canada	NULL
(	NULL
to	NULL
J.H	NULL
.	NULL
)	NULL

.	NULL

A.R	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
studentship	NULL
from	NULL
FCAR	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
an	NULL
MRC	NULL
Scientist	NULL
Award	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Andreesen	NULL
,	NULL
R.	NULL
,	NULL
W.	NULL
Brugger	NULL
,	NULL
R.	NULL
Kunze	NULL
,	NULL
W.	NULL
Stille	NULL
,	NULL
and	NULL
H.	NULL
von	NULL
Briesen	NULL
.	NULL

1990	NULL
.	NULL

Defective	NULL
monocyte	NULL
to	NULL
macrophage	NULL
differentiation	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

141:217-224	NULL
.	NULL

2	NULL
.	NULL

Bachelerie	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1991	NULL
.	NULL

HIV	NULL
enhancer	NULL
activity	NULL
perpetuated	NULL
by	NULL
NF-kB	NULL
induction	NULL
on	NULL
infection	NULL
of	NULL
monocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:709-712	NULL
.	NULL

3	NULL
.	NULL

Baeuerie	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
65-kD	NULL
subunit	NULL
of	NULL
active	NULL
NF-KB	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
IB	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1689-1698	NULL
.	NULL

4	NULL
.	NULL

Baeverle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
inducible	NULL
transcription	NULL
activator	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
regulation	NULL
by	NULL
distinct	NULL
protein	NULL
subunits	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072:63-80	NULL
.	NULL

5	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
E.	NULL
P.	NULL
Dixon	NULL
,	NULL
N.	NULL
J.	NULL
Peffer	NULL
,	NULL
H.	NULL
Bogerd	NULL
,	NULL
S.	NULL
Doerre	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
65-kDa	NULL
subunit	NULL
of	NULL
human	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
functions	NULL
as	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
and	NULL
a	NULL
target	NULL
for	NULL
v-rel-mediated	NULL
repression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1875-1879.	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
R.	NULL
I.	NULL
Scheinman	NULL
,	NULL
S.	NULL
Haskill	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

IxB	NULL
interacts	NULL
with	NULL
the	NULL
nuclear	NULL
localization	NULL
sequences	NULL
of	NULL
the	NULL
subunits	NULL
of	NULL
NF-kB	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
cytoplasmic	NULL
retention	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:1899-1913.	NULL
.	NULL

Beutler	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
A.	NULL
Cerami	NULL
.	NULL

1988	NULL
.	NULL

Tumor	NULL
necrosis	NULL
,	NULL
cachexia	NULL
,	NULL
shock	NULL
and	NULL
inflammation	NULL
:	NULL
a	NULL
common	NULL
mediator	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

57:505-518.	NULL
.	NULL

Blank	NULL
,	NULL
V.	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1992.	NULL
and	NULL
related	NULL
proteins	NULL
:	NULL
Rel/dorsal	NULL
homologies	NULL
meet	NULL
ankyrin-like	NULL
repeats	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:135-140.	NULL
.	NULL

Bose	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

The	NULL
Rel	NULL
family	NULL
:	NULL
models	NULL
for	NULL
transcriptional	NULL
regulation	NULL
and	NULL
oncogenic	NULL
transformation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1114:1-17	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
J.	NULL
Villalobos	NULL
,	NULL
P.	NULL
R.	NULL
Burd	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
mitogen-inducible	NULL
gene	NULL
encoding	NULL
a	NULL
B	NULL
DNA-binding	NULL
protein	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
rel	NULL
oncogene	NULL
and	NULL
to	NULL
cell-cycle	NULL
motifs	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
348:76-80	NULL
.	NULL

Brownell	NULL
,	NULL
D.	NULL
,	NULL
N.	NULL
Mittereder	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Rice	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
human	NULL
re/	NULL
proto-oncogene	NULL
cDNA	NULL
containing	NULL
an	NULL
Alu	NULL
fragment	NULL
as	NULL
a	NULL
potential	NULL
coding	NULL
exon	NULL
.	NULL

Oncogene	NULL
4:935-942	NULL
.	NULL

D'Addario	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Coordinate	NULL
enhancement	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
l-infected	NULL
promonocytic	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:6080-6089	NULL
.	NULL

D'Addario	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
HIV-1	NULL
infected	NULL
myelomonoblastic	NULL
cells	NULL
by	NULL
phorbol	NULL
ester	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148	NULL
:	NULL
1222-1229	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
S.	NULL
W.	NULL
Kessler	NULL
,	NULL
J.	NULL
M.	NULL
Orenstine	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
E.	NULL
S.	NULL
Jaffe	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Infection	NULL
and	NULL
replication	NULL
of	NULL
HIV-1	NULL
in	NULL
purified	NULL
progenitor	NULL
cells	NULL
of	NULL
normal	NULL
human	NULL
bone	NULL
mar-row	NULL
.	NULL

Science	NULL
242:919-922	NULL
.	NULL

Franzoso	NULL
,	NULL
G.	NULL
,	NULL
V.	NULL
Bours	NULL
,	NULL
S.	NULL
Park	NULL
,	NULL
M.	NULL
Tomita-Yamaguchi	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebentist	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
candidate	NULL
oncoprotein	NULL
Bcl-3	NULL
is	NULL
an	NULL
antagonist	NULL
of	NULL
pS50/NF-	NULL
«	NULL
B-mediated	NULL
inhibition	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
359:339-342	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1992	NULL
.	NULL

Independent	NULL
modes	NULL
of	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:775-782	NULL
.	NULL

Gazzolo	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
K.	NULL
Mace	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV1	NULL
replication	NULL
in	NULL
promonocytic	NULL
U937	NULL
cells	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

141:259-265	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
in	NULL
vitro	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
344	NULL
:	NULL
678-682	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
M.	NULL
Gifford	NULL
,	NULL
L.	NULL
R.	NULL
Riviere	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
homology	NULL
to	NULL
rel	NULL
and	NULL
dorsal	NULL
.	NULL

Cell	NULL
62:1019-1029	NULL
.	NULL

Gill	NULL
,	NULL
P.	NULL
S.	NULL
1991	NULL
.	NULL

Pathogenesis	NULL
of	NULL
HIV-related	NULL
malignancies	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Oncol	NULL
.	NULL

3:867-871	NULL
.	NULL

Gilmore	NULL
,	NULL
T.	NULL
D.	NULL
1990	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
,	NULL
KBF1	NULL
,	NULL
dorsal	NULL
and	NULL
related	NULL
matters	NULL
.	NULL

Cell	NULL
62:841-843	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051.	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-	NULL
<	NULL
B	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:70-73	NULL
.	NULL

Grossched	NULL
!	NULL

1	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1985	NULL
.	NULL

Cell-type	NULL
specificity	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
at	NULL
least	NULL
three	NULL
DNA	NULL
sequence	NULL
elements	NULL
.	NULL

Cell	NULL
41:885-897.	NULL
.	NULL

Haskill	NULL
,	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Beg	NULL
,	NULL
S.	NULL
M.	NULL
Tompkins	NULL
,	NULL
J.	NULL
S.	NULL
Morris	NULL
,	NULL
A.	NULL
D.	NULL
Yurochko	NULL
,	NULL
A.	NULL
Sampson-Johannes	NULL
,	NULL
K.	NULL
Mondal	NULL
,	NULL
P.	NULL
Ralph	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1991	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
immediate-early	NULL
gene	NULL
induced	NULL
in	NULL
adherent	NULL
monocytes	NULL
that	NULL
encodes	NULL
IxB-like	NULL
activity	NULL
.	NULL

Cell	NULL
65:1281-1289	NULL
.	NULL

Hiscott	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Aiper	NULL
,	NULL
L.	NULL
Cohen	NULL
,	NULL
J.-F.	NULL
Leblanc	NULL
,	NULL
L.	NULL
Spotza	NULL
,	NULL
A.	NULL
Wong	NULL
,	NULL
and	NULL
S.	NULL
Xanthoudakis	NULL
.	NULL

1989	NULL
.	NULL

Induction	NULL
of	NULL
human	NULL
interferon	NULL
gene	NULL
expression	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
nuclear	NULL
factor	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43.	NULL
virus	NULL
enhancer	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:2557-2566	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
L.	NULL
D.	NULL
Kerr	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
and	NULL
I.	NULL
Verma	NULL
.	NULL

1992	NULL
.	NULL

IxBy	NULL
,	NULL
a	NULL
70	NULL
kd	NULL
protein	NULL
identical	NULL
to	NULL
the	NULL
c-terminal	NULL
half	NULL
of	NULL
p110	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
IkB	NULL
family	NULL
.	NULL

Cell	NULL
68:1109-1120.	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
L.	NULL
D.	NULL
Kerr	NULL
,	NULL
L.	NULL
J.	NULL
Ransone	NULL
,	NULL
E.	NULL
Bengal	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1991.	NULL
c-rel	NULL
activates	NULL
but	NULL
v-rel	NULL
suppresses	NULL
transcription	NULL
from	NULL
kB	NULL
sites	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
:	NULL
3715-3719	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
L.	NULL
D.	NULL
Kerr	NULL
,	NULL
D.	NULL
Rashid	NULL
,	NULL
N.	NULL
Davis	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Bose	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

Direct	NULL
association	NULL
of	NULL
pp40/IxBB	NULL
with	NULL
rel/NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
:	NULL
role	NULL
of	NULL
ankyrin	NULL
repeats	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:4333-4337	NULL
.	NULL

Kerr	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
P.	NULL
Wamsley	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
P.	NULL
Chiao	NULL
,	NULL
G.	NULL
Nabel	NULL
,	NULL
T.	NULL
W.	NULL
McKeithan	NULL
,	NULL
P.	NULL
A.	NULL
Baeurie	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
proto-oncogene	NULL
BCL	NULL
-3	NULL
encodes	NULL
an	NULL
IxB	NULL
protein	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:2352-2363	NULL
.	NULL

Kerr	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
J.	NULL
I.	NULL
Inoue	NULL
,	NULL
N.	NULL
Davis	NULL
,	NULL
E.	NULL
Link	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
,	NULL
H.	NULL
R.	NULL
Bose	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
rel-associated	NULL
pp40	NULL
protein	NULL
prevents	NULL
DNA	NULL
binding	NULL
of	NULL
rel	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
relationship	NULL
with	NULL
IxBB	NULL
and	NULL
regulation	NULL
by	NULL
phosphorylation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:1464-1476	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
F.	NULL
Logeat	NULL
,	NULL
J.	NULL
Vandekerckhove	NULL
,	NULL
F.	NULL
Lottspe-ich	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

Urban	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
DNA-binding	NULL
subunit	NULL
of	NULL
NF-KB	NULL
is	NULL
identical	NULL
to	NULL
factor	NULL
KBF1	NULL
and	NULL
homologous	NULL
to	NULL
the	NULL
re/	NULL
oncogene	NULL
product	NULL
.	NULL

Cell	NULL
62:1007-1018	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

Selection	NULL
of	NULL
optimal	NULL
xB/re/	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
interaction	NULL
of	NULL
both	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
DNA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4412-4421	NULL
.	NULL

Lacoste	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Cohen	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1991	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Virology	NULL
184:553	NULL
.	NULL

Lacoste	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Cell-specific	NULL
differences	NULL
in	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
regulatory	NULL
elements	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
and	NULL
beta	NULL
interferon	NULL
promoters	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
:	NULL
4726-4734	NULL
.	NULL

Lattion	NULL
,	NULL
A.-L.	NULL
,	NULL
E.	NULL
Espel	NULL
,	NULL
P.	NULL
Reichenbach	NULL
,	NULL
C.	NULL
Fromental	NULL
,	NULL
P.	NULL
Bucher	NULL
,	NULL
A.	NULL
Israel	NULL
,	NULL
P.	NULL
Baeuerle	NULL
,	NULL
N.	NULL
Rice	NULL
,	NULL
and	NULL
M.	NULL
Nabholz	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
new	NULL
tissue-specific	NULL
transcription	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
enhancer	NULL
TC-II	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:5217-5227	NULL
.	NULL

Leblanc	NULL
,	NULL
J.-F.	NULL
,	NULL
L.	NULL
Cohen	NULL
,	NULL
M.	NULL
Rodrigues	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Synergism	NULL
between	NULL
distinct	NULL
enhanson	NULL
domains	NULL
in	NULL
viral	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
beta	NULL
interferon	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:3987-3993	NULL
.	NULL

Locardi	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Petrini	NULL
,	NULL
G.	NULL
Boccoli	NULL
,	NULL
U.	NULL
Testa	NULL
,	NULL
C.	NULL
Dieffenbach	NULL
,	NULL
S.	NULL
Butto	NULL
,	NULL
and	NULL
F.	NULL
Belardelli	NULL
.	NULL

1990	NULL
.	NULL

Increased	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
U937	NULL
cells	NULL
upon	NULL
in	NULL
vitro	NULL
differentiation	NULL
by	NULL
hydroxyvitamin	NULL
D3	NULL
:	NULL
roles	NULL
of	NULL
interferon	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
regulation	NULL
of	NULL
HIV	NULL
production	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5874-5882	NULL
.	NULL

Meltzer	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
D.	NULL
R.	NULL
Skillman	NULL
,	NULL
P.	NULL
J.	NULL
Gomatos	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1990	NULL
.	NULL

Role	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:169-194.	NULL
.	NULL

Merrill	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1989	NULL
.	NULL

Interleu-	NULL
kin-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
can	NULL
be	NULL
induced	NULL
from	NULL
mononuclear	NULL
phagocytes	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
binding	NULL
to	NULL
the	NULL
CD4	NULL
receptor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4404-4408	NULL
.	NULL

Meyer	NULL
,	NULL
R.	NULL
,	NULL
E.	NULL
H.	NULL
Hatada	NULL
,	NULL
H.	NULL
P.	NULL
Hohmann	NULL
,	NULL
M.	NULL
Haiker	NULL
,	NULL
C.	NULL
Bartsch	NULL
,	NULL
U.	NULL
Rothlisberger	NULL
,	NULL
H.	NULL
W.	NULL
Lahm	NULL
,	NULL
E.	NULL
J.	NULL
Schlaeger	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
Van	NULL
Loon	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1991	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
DNA-binding	NULL
subunit	NULL
of	NULL
human	NULL
nuclear	NULL
factor	NULL
xB	NULL
:	NULL
the	NULL
level	NULL
of	NULL
its	NULL
mRNA	NULL
is	NULL
strongly	NULL
regulated	NULL
by	NULL
phorbol	NULL
ester	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
8	NULL
$	NULL
8:966-970	NULL
.	NULL

Nakayama	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Shimizu	NULL
,	NULL
K.	NULL
Mitomo	NULL
,	NULL
T.	NULL
Watanabe	NULL
,	NULL
S.-I	NULL
.	NULL

Okamoto	NULL
,	NULL
and	NULL
K.-I	NULL
.	NULL

Yamamoto	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
lymphoid	NULL
cell-specific	NULL
nuclear	NULL
factor	NULL
containing	NULL
c-Rel-like	NULL
proteins	NULL
preferentially	NULL
interacts	NULL
with	NULL
interleukin-6	NULL
<	NULL
B-related	NULL
motifs	NULL
whose	NULL
activities	NULL
are	NULL
repressed	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1736-1746	NULL
.	NULL

Narayanan	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
F.	NULL
Klement	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
K.	NULL
A.	NULL
Higgins	NULL
,	NULL
and	NULL
INDUCTION	NULL
OF	NULL
NF-kB	NULL
ACTIVITY	NULL
BY	NULL
VIRUS	NULL
INFECTION	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

54a	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

5245	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
naturally	NULL
occurring	NULL
transforming	NULL
variant	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Science	NULL
256:367.	NULL
.	NULL

Neri	NULL
,	NULL
A.	NULL
,	NULL
C.-C.	NULL
Chang	NULL
,	NULL
L.	NULL
Lombardi	NULL
,	NULL
M.	NULL
Salina	NULL
,	NULL
P.	NULL
Corradini	NULL
,	NULL
A.	NULL
T.	NULL
Maiolo	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1991	NULL
.	NULL

B	NULL
cell	NULL
Iymphoma-associated	NULL
chromosomal	NULL
translocation	NULL
involves	NULL
candidate	NULL
oncogene	NULL
lyt-10	NULL
,	NULL
homologous	NULL
to	NULL
NF-kB	NULL
pSQ	NULL
.	NULL

Cell	NULL
67:1075-1087	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
binding	NULL
and	NULL
I	NULL
«	NULL
B	NULL
inhibition	NULL
of	NULL
the	NULL
cloned	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
a	NULL
re/-related	NULL
polypeptide	NULL
.	NULL

Cell	NULL
64:961-969	NULL
.	NULL

Pautrat	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Suzan	NULL
,	NULL
D.	NULL
Salaun	NULL
,	NULL
P.	NULL
Corbeau	NULL
,	NULL
C.	NULL
Allasia	NULL
,	NULL
G.	NULL
Morel	NULL
,	NULL
and	NULL
P.	NULL
Filippi	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
of	NULL
U937	NULL
cells	NULL
promotes	NULL
cell	NULL
differentiation	NULL
and	NULL
a	NULL
new	NULL
pathway	NULL
of	NULL
viral	NULL
assembly	NULL
.	NULL

Virology	NULL
179:749-758	NULL
.	NULL

Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
R.	NULL
M.	NULL
Ten	NULL
,	NULL
C.	NULL
Bessia	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1992	NULL
.	NULL

NF-xB-dependent	NULL
induction	NULL
of	NULL
the	NULL
NF-kB	NULL
p50	NULL
subunit	NULL
gene	NULL
promoter	NULL
underlies	NULL
self-perpetuation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transcription	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7826-7830.	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
N.	NULL
R.	NULL
Rice	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Distinct	NULL
combinations	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
determine	NULL
the	NULL
specificity	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1529-1533	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cytokines	NULL
and	NULL
pharmacologic	NULL
agents	NULL
on	NULL
chronic	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
8:191-207	NULL
.	NULL

Raziuddin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Mikovits	NULL
,	NULL
I.	NULL
Calvert	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
H.-F.	NULL
Kung	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
.	NULL

1991	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
in	NULL
monocytes	NULL
:	NULL
role	NULL
of	NULL
the	NULL
65-kDa	NULL
plus	NULL
50-kDa	NULL
NF-	NULL
«	NULL
B	NULL
dimer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:9426-9430	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
M.	NULL
L.	NULL
MacKichan	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
precursor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
has	NULL
IxB-like	NULL
functions	NULL
.	NULL

Cell	NULL
71:243-253	NULL
.	NULL

Riviere	NULL
,	NULL
Y.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1991	NULL
.	NULL

Processing	NULL
of	NULL
the	NULL
precursor	NULL
of	NULL
NF-xB	NULL
by	NULL
the	NULL
HIV-1	NULL
protease	NULL
during	NULL
acute	NULL
infection	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:625-626	NULL
.	NULL

Rosenberg	NULL
,	NULL
Z.	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Immunopathogenic	NULL
mechanisms	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

50:149-156	NULL
.	NULL

Rosenberg	NULL
,	NULL
Z.	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Immunopathogenesis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2382-2390	NULL
.	NULL

Roulston	NULL
,	NULL
A	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
F.	NULL
Boulerice	NULL
,	NULL
S.	NULL
Caplan	NULL
,	NULL
M.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1992	NULL
.	NULL

Induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
NF-	NULL
«	NULL
B-like	NULL
activities	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
infection	NULL
of	NULL
human	NULL
myelomonoblastic	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:751-763	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
P.	NULL
J.	NULL
Dillon	NULL
,	NULL
R.	NULL
Schreck	NULL
,	NULL
T.	NULL
Henkel	NULL
,	NULL
C.	NULL
H.	NULL
Chen	NULL
,	NULL
M.	NULL
Maher	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1991	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
rel-related	NULL
human	NULL
cDNA	NULL
that	NULL
potentially	NULL
encodes	NULL
the	NULL
65-kD	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Science	NULL
251:1490-1493	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J.	NULL
F.	NULL
Klement	NULL
,	NULL
T.	NULL
A.	NULL
Coleman	NULL
,	NULL
M.	NULL
Maher	NULL
,	NULL
C.-H.	NULL
Chen	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

I-Rel	NULL
:	NULL
a	NULL
novel	NULL
re/-related	NULL
protein	NULL
that	NULL
inhibits	NULL
transcriptional	NULL
activity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:745-760	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
R.	NULL
Narayanan	NULL
,	NULL
J.	NULL
F.	NULL
Klement	NULL
,	NULL
C.-H.	NULL
Chen	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
characterization	NULL
of	NULL
the	NULL
NF-kB	NULL
p65	NULL
transcriptional	NULL
activator	NULL
and	NULL
an	NULL
alternatively	NULL
spliced	NULL
derivative	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:444-454	NULL
.	NULL

Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
P.	NULL
Bull	NULL
,	NULL
M.	NULL
Takamiya	NULL
,	NULL
V.	NULL
Bours	NULL
,	NULL
U.	NULL
Siebenlist	NULL
,	NULL
P.	NULL
Dobrzanski	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1992	NULL
.	NULL

RelB	NULL
,	NULL
a	NULL
new	NULL
Rel	NULL
family	NULL
transcription	NULL
activator	NULL
that	NULL
can	NULL
interact	NULL
with	NULL
p50-NF-	NULL
«	NULL
kB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:674-684.	NULL
.	NULL

Schmid	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
N.	NULL
D.	NULL
Perkins	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
P.	NULL
C.	NULL
Andrews	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1991	NULL
.	NULL

Cloning	NULL
of	NULL
an	NULL
NF-kB	NULL
subunit	NULL
which	NULL
stimulates	NULL
HIV	NULL
transcription	NULL
in	NULL
synergy	NULL
with	NULL
p65	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
352:733-736	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeverie	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
p65	NULL
subunit	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
strong	NULL
transcription	NULL
activating	NULL
potential	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:3805-3817	NULL
.	NULL

Schutze	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Potthoff	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
D.	NULL
Berkovic	NULL
,	NULL
K.	NULL
Wieg-mann	NULL
,	NULL
and	NULL
M.	NULL
Kronke	NULL
.	NULL

1992	NULL
.	NULL

TNF	NULL
activates	NULL
NF-kB	NULL
by	NULL
phos-phatidylcholine-specific	NULL
-	NULL
phospholiase	NULL
-	NULL
C-induced	NULL
-	NULL
``	NULL
acidic	NULL
``	NULL
5246	NULL
63	NULL
.	NULL

ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

sphingomyelin	NULL
breakdown	NULL
.	NULL

Cell	NULL
71:765-776	NULL
.	NULL

Shreck	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rieber	NULL
,	NULL
and	NULL
P.	NULL
Bacuerle	NULL
.	NULL

1991	NULL
.	NULL

Reactive	NULL
oxygen	NULL
intermediates	NULL
as	NULL
apparently	NULL
widely	NULL
used	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
and	NULL
HIV-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2247-2258	NULL
.	NULL

63a.Sun	NULL
,	NULL
S.-C.	NULL
,	NULL
P.	NULL
A.	NULL
Ganchi	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

1993	NULL
.	NULL

NF-kB	NULL
controls	NULL
expression	NULL
of	NULL
inhibitor	NULL
IxBa	NULL
:	NULL
evidence	NULL
for	NULL
an	NULL
inducible	NULL
autoregulatory	NULL
pathway	NULL
.	NULL

Science	NULL
259:1912-1915	NULL
.	NULL

Suzan	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Salaun	NULL
,	NULL
C.	NULL
Neuveut	NULL
,	NULL
B.	NULL
Spire	NULL
,	NULL
I.	NULL
Hirsch	NULL
,	NULL
P.	NULL
Le	NULL
Bouteiller	NULL
,	NULL
G.	NULL
Querat	NULL
,	NULL
and	NULL
J.	NULL
Sire	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
HIV	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:377-383	NULL
.	NULL

Thanos	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
is	NULL
required	NULL
for	NULL
NF-kB	NULL
dependent	NULL
virus	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
IFN-	NULL
gene	NULL
.	NULL

Cell	NULL
71:777-789	NULL
.	NULL

Tucker	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
M.	NULL
B.	NULL
Lilly	NULL
,	NULL
L.	NULL
Heck	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
T.	NULL
Rado	NULL
.	NULL

1987	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
new	NULL
human	NULL
diploid	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
PLB-985	NULL
)	NULL
with	NULL
granulocytic	NULL
and	NULL
monocytic	NULL
differentiating	NULL
capacity	NULL
.	NULL

Blood	NULL
70:372-378	NULL
.	NULL

Turpin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
M.	NULL
Vargo	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Meltzer	NULL
.	NULL

1992	NULL
.	NULL

Enhanced	NULL
68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

HIV-1	NULL
replication	NULL
in	NULL
retinoid	NULL
treated	NULL
monocytes	NULL
.	NULL

Retinoid	NULL
effects	NULL
mediated	NULL
through	NULL
mechanisms	NULL
related	NULL
to	NULL
cell	NULL
differentiation	NULL
and	NULL
to	NULL
a	NULL
direct	NULL
transcriptional	NULL
action	NULL
on	NULL
viral	NULL
gene	NULL
expres-sion	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:2539-2546	NULL
.	NULL

Urban	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
65-kD	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
receptor	NULL
for	NULL
IxB	NULL
and	NULL
a	NULL
modulator	NULL
of	NULL
DNA-binding	NULL
specificity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1975-1984	NULL
.	NULL

Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
recognition	NULL
of	NULL
cognate	NULL
sequences	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

3:279-288	NULL
.	NULL

Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
R.	NULL
Schreck	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
contacts	NULL
DNA	NULL
by	NULL
a	NULL
heterodimer	NULL
of	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
subunit	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:1817-1825	NULL
.	NULL

Wulezyn	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
M.	NULL
Naumann	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1992	NULL
.	NULL

Candidate	NULL
proto-oncogene	NULL
bel-3	NULL
encodes	NULL
a	NULL
subunit-specific	NULL
inhibitor	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
358:597-599	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

Purified	NULL
human	NULL
I	NULL
«	NULL
B	NULL
can	NULL
rapidly	NULL
dissociate	NULL
the	NULL
complex	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
with	NULL
its	NULL
cognate	NULL
DNA	NULL
.	NULL

Cell	NULL
61:255-265	NULL
.	NULL

